WO1995010615A1 - Subtilisin variants - Google Patents

Subtilisin variants Download PDF

Info

Publication number
WO1995010615A1
WO1995010615A1 PCT/US1994/011562 US9411562W WO9510615A1 WO 1995010615 A1 WO1995010615 A1 WO 1995010615A1 US 9411562 W US9411562 W US 9411562W WO 9510615 A1 WO9510615 A1 WO 9510615A1
Authority
WO
WIPO (PCT)
Prior art keywords
subtilisin
ala
ser
gly
amino acid
Prior art date
Application number
PCT/US1994/011562
Other languages
French (fr)
Inventor
Thomas P. Graycar
Richard R. Bott
Lori J. Wilson
Original Assignee
Genencor International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69434187T priority Critical patent/DE69434187T2/en
Priority to PL94313942A priority patent/PL178478B1/en
Priority to KR1019960701923A priority patent/KR100344976B1/en
Priority to DK94931345T priority patent/DK0723590T3/en
Application filed by Genencor International, Inc. filed Critical Genencor International, Inc.
Priority to AU80157/94A priority patent/AU700373B2/en
Priority to JP51201395A priority patent/JP4086207B2/en
Priority to AT94931345T priority patent/ATE284962T1/en
Priority to BR9407825A priority patent/BR9407825A/en
Priority to EP94931345A priority patent/EP0723590B1/en
Priority to CA002173973A priority patent/CA2173973C/en
Priority to RU96109372A priority patent/RU2136756C1/en
Publication of WO1995010615A1 publication Critical patent/WO1995010615A1/en
Priority to FI961631A priority patent/FI119697B/en
Priority to NO19961468A priority patent/NO325568B1/en
Priority to HK97102150A priority patent/HK1000649A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38609—Protease or amylase in solid compositions only
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus

Definitions

  • the present invention relates to novel carbonyl hydrolase variants having an amino acid sequence wherein a plurality of amino acid residues of a precursor carbonyl hydrolase, specifically those at positions corresponding or equivalent to residue +76 in combination with one or more of the residues selected from the group consisting of +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 in Bacillus amyloliquefaciens
  • mutant/variant carbonyl hydrolases in general, are obtained by in vitro modification of a precursor DNA sequence encoding a naturally-occurring or recombinant carbonyl hydrolase to encode the
  • Serine proteases are a subgroup of carbonyl hydrolase. They comprise a diverse class of enzymes having a wide range of
  • subtilisin is a serine endoprotease (MW 27,500) which is secreted in large amounts from a wide variety of Bacillus species and other microorganisms.
  • the protein sequence of subtilisin has been determined from at least four different species of Bacillus .
  • subtilisin is genetically unrelated to the mammalian serine proteases, it has a similar active site structure.
  • subtilisin containing covalently bound peptide inhibitors Robottus, J.D., et al. (1972), Biochemistry, 11:2439-2449
  • product complexes Robottus, J.D., et al. (1976), J. Biol. Chem., 251:1097-1103
  • subtilisin Philipp, M., et al. (1983), Mol. Cell. Biochem., 51:5-32; Svendsen, B. (1976), Carlsberg Res.
  • US Patent 5,182,204 discloses the modification of the amino acid +224 residue in Bacillus amyloliquefaciens subtilisin and equivalent positions in other subtilisins which may be modified by way of substitution, insertion or deletion and which may be combined with modifications to the residues identified in US Patent 4,760,025 (RE 34,606) to form useful subtilisin mutants or variants.
  • US Patent 5,155,033 discloses similar mutant subtilisins having a modification at an equivalent position to +225 of B . amyloliquefaciens subtilisin.
  • US Patents 5,185,258 and 5,204,015 disclose mutant subtilisins having a modification at positions +123 and/or +274. The disclosure of these patents is incorporated herein by reference, as is the disclosure of US Patent Application SN 07/898,382, which discloses the
  • carbonyl hydrolase preferably subtilisin
  • Such variants generally have at least one property which is different from the same property of the carbonyl hydrolase precursor from which the amino acid sequence of said variant is derived.
  • Another object of the invention is to provide host cells transformed with such vectors, as well as host cells which are capable of expressing such DNA to produce carbonyl hydrolase variants either intracellularly or extracellularly.
  • the invention includes non-naturally-occurring carbonyl hydrolase variants having a different proteolytic activity, stability, substrate specificity, pH profile and/or performance characteristic as compared to the precursor carbonyl hydrolase from which the amino acid sequence of the variant is derived.
  • the precursor carbonyl hydrolase may be a naturally-occurring carbonyl hydrolase or recombinant hydrolase.
  • such carbonyl hydrolase variants have an amino acid sequence not found in nature, which is derived by replacement of a plurality of amino acid residues of a precursor carbonyl hydrolase with different amino acids.
  • the plurality of amino acid residues of the precursor enzyme correspond to position +76 in combination with one or more of the following residues +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274, where the numbered position corresponds to naturally-occurring subtilisin from Bacillus
  • invention comprise replacement of amino acid residue +76 in
  • variant enzymes of the present invention comprise the
  • the variant enzymes of the present invention comprise the substitution, deletion or insertion of an amino acid residue in the following combination of residues: 76/99; 76/104; 76/99/104; 76/103/104; 76/104/107; 76/101/103/104; 76/99/101/103/104 and 76/101/104 of B . amyloliquefaciens subtilisin.
  • the invention also includes variant DNA sequences encoding such carbonyl hydrolase or subtilisin variants.
  • variant DNA sequences are derived from a precursor DNA sequence which encodes a naturally-occurring or recombinant precursor enzyme.
  • the variant DNA sequences are derived by modifying the precursor DNA sequence to encode the substitution of one or more specific amino acid residues encoded by the precursor DNA sequence corresponding to positions 76, 99, 101, 103, 104, 107, 123, 27, 105, 109, 126, 128, 135, 156, 166, 195, 197, 204, 206, 210, 216, 217, 218, 222, 260, 265 and/or 274 in Bacillus amyloliquefaciens or any combination thereof.
  • amyloliquefaciens which has become the conventional method for identifying residue positions in all subtilisins
  • the preferred precursor DNA sequence useful in the present invention is the DNA sequence of Bacillus lentus as shown in Fig. 6 (Seq ID No.11).
  • variant DNA sequences of the present invention encode the insertion or substitution of the amino acid residue 76 in
  • the variant DNA sequences encode the substitution or insertion of amino acid residues in the following combinations: 76/99; 76/101; 76/103; 76/104; 76/107; 76/123; 76/99/101; 76/99/103; 76/99/104; 76/101/103; 76/101/104; 76/103/104; 76/104/107; 76/104/123;
  • the variant DNA sequences encode for the modification of the following combinations of residues: 76/99; 76/104; 76/99/104; 76/103/104; 76/104/107; 76/101/103/104; 76/99/101/103/104 and 76/101/104.
  • These recombinant DNA sequences encode carbonyl hydrolase variants having a novel amino acid sequence and, in general, at least one property which is substantially different from the same property of the enzyme encoded by the precursor carbonyl hydrolase DNA sequence. Such properties include proteolytic activity, substrate specificity, stability, altered pH profile and/or enhanced performance
  • the present invention encompasses the substitution of any of the nineteen naturally occurring L-amino acids at the designated amino acid residue positions.
  • Such substitutions can be made in any precursor subtilisin (procaryotic, eucaryotic, mammalian, etc.).
  • the substitution to be made at each of the identified amino acid residue positions include but are not limited to:
  • substitutions at position 76 including D, H, E, G, F, K, P and N; substitutions at position 99 including D, T, N, Q, G and S;
  • substitutions at position 101 including G, D, K, L, A, E, S and R; substitutions at position 103 including Q, T, D, E, Y, K, G, R, S and A; substitutions at position 104 including all nineteen
  • substitutions at position 166 including all nineteen naturally-occurring amino acids; substitutions at position 195 including E; substitutions at position 197 including E; substitutions at position 204 including A, G, C, S and D; substitutions at position 206 including L, Y, N, D and E; substitutions at position 210 including L, I, S, C and F; substitutions at position 216 including V, E, T and K; substitutions at position 217 including all nineteen
  • the specifically preferred amino acid(s) to be substituted at each such position are designated below in Table I. Although specific amino acids are shown in Table I, it should be understood that any amino acid may be substituted at the identified residues. Table I
  • the invention includes expression vectors containing such variant carbonyl hydrolase DNA sequences, as well as host cells transformed with such vectors which are capable of producing such variants.
  • the invention also relates to detergent compositions comprising the carbonyl hydrolase variants of the invention.
  • Figs. 1 A-C depict the DNA and amino acid sequence for Bacillus amyloliquefaciens subtilisin and a partial restriction map of this gene (Seq. ID No.6).
  • Fig. 2 depicts the conserved amino acid residues among subtilisins from Bacillus amyloliquefaciens (BPN)' and Bacillus lentus (wild-type).
  • Figs. 3A and 3B depict the amino acid sequence of four subtilisins.
  • the top line represents the amino acid sequence of subtilisin from Bacillus amyloliquefaciens subtilisin (also sometimes referred to as subtilisin BPN') (Seq. ID No.7).
  • the second line depicts the amino acid sequence of subtilisin from Bacillus subtilis (Seq. ID No.8).
  • the third line depicts the amino acid sequence of subtilisin from B. licheniformis (Seq. ID No.9).
  • the fourth line depicts the amino acid sequence of subtilisin from Bacillus lentus (also referred to as subtilisin 309 in PCT WO89/06276) (Seq. ID No.10).
  • the symbol * denotes the absence of specific amino acid residues as compared to subtilisin BPN'.
  • Fig. 4 depicts the construction of plasmid GGA274.
  • Fig. 5 depicts the construction of GGT274 which is an intermediate to certain expression plasmids used in this application.
  • Figs. 6A and 6B depict the DNA and amino acid sequence of subtilisin from Bacillus lentus (Seq. ID No.11).
  • the mature subtilisin protein is coded by the codons beginning at the codon GCG (334-336)
  • Figs. 7A and 7B depict the DNA and amino acid sequence of a
  • N76D/S103A/V104I (Seq. ID No.12).
  • the DNA in this figure has been modified by the methods described to encode aspartate at position 76, alanine at position 103 and isoleucine at position 104.
  • the mature subtilisin variant protein is coded by the codons beginning at the codon GCG (334-336) corresponding to Ala.
  • Fig. 8 depicts the construction of vector pBCDAICAT.
  • Fig. 9 depicts the construction of vector pUCCATFNA.
  • Fig. 10 shows the stability of a preferred mutant enzyme compared to wild-type, in a liquid detergent formulation.
  • subtilisin at an amino acid residue equivalent to +76 in Bacillus amyloliquefaciens subtilisin produces subtilisin variants exhibiting altered stability (e.g., modified autoproteolytic stability) over precursor subtilisins.
  • altered stability e.g., modified autoproteolytic stability
  • in vitro mutation at residues equivalent to +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 in Bacillus
  • amyloliquefaciens subtilisin alone or in combination with each other and in any combination with +76 mutations, produce subtilisin variants exhibiting altered proteolytic activity, altered thermal stability, altered pH profile, altered substrate specificity and/or altered performance characteristics.
  • Carbonyl hydrolases are enzymes which hydrolyze compounds containing
  • Naturally-occurring carbonyl hydrolases principally include
  • hydrolases e.g., peptide hydrolases such as subtilisins or
  • Peptide hydrolases include ⁇ -aminoacylpeptide hydrolase, peptidylamino acid hydrolase, acylamino hydrolase, serine carboxypeptidase, metallocarboxypeptidase, thiol proteinase, carboxylproteinase and metalloproteinase. Serine, metallo, thiol and acid proteases are included, as well as endo and exo-proteases .
  • Recombinant carbonyl hydrolase refers to a carbonyl hydrolase in which the DNA sequence encoding the naturally-occurring carbonyl hydrolase is modified to produce a mutant DNA sequence which encodes the substitution, insertion or deletion of one or more amino acids in the carbonyl hydrolase amino acid sequence.
  • Subtilisins are bacterial or fungal carbonyl hydrolases which generally act to cleave peptide bonds of proteins or peptides.
  • subtilisin means a naturally-occurring subtilisin or a recombinant subtilisin. A series of naturally-occurring subtilisin.
  • subtilisins is known to be produced and often secreted by various microbial species. Amino acid sequences of the members of this series are not entirely homologous. However, the subtilisins in this series exhibit the same or similar type of proteolytic activity.
  • This class of serine proteases shares a common amino acid sequence defining a catalytic triad which distinguishes them from the chymotrypsin related class of serine proteases.
  • the subtilisins and chymotrypsin related serine proteases both have a catalytic triad comprising aspartate, histidine and serine. In the subtilisin related proteases the relative order of these amino acids, reading from the amino to carboxy terminus, is aspartate-histidine-serine.
  • subtilisin refers to a serine protease having the catalytic triad of subtilisin related proteases. Examples include but are not limited to the subtilisins identified in Fig. 3 herein.
  • Recombinant subtilisin refers to a subtilisin in which the DNA sequence encoding the subtilisin is modified to produce a variant (or mutant) DNA sequence which encodes the substitution, deletion or insertion of one or more amino acids in the naturally-occurring subtilisin amino acid sequence.
  • Suitable methods to produce such modification include those disclosed in US Patent 4,760,025 (RE 34,606), US Patent 5,204,015 and US Patent 5,185,258.
  • Non-human carbonyl hydrolases and the DNA encoding them may be obtained from many procaryotic and eucaryotic organisms. Suitable examples of procaryotic organisms include gram negative organisms such as E. coli or Pseudomonas and gram positive bacteria such as Micrococcus or Bacillus . Examples of eucaryotic organisms from which carbonyl hydrolase and their genes may be obtained include yeast such as Saccharomyces cerevisiae, fungi such as Aspergillus sp. and non-human mammalian sources such as, for example, bovine sp. from which the gene encoding the carbonyl hydrolase chymosin can be obtained.
  • yeast such as Saccharomyces cerevisiae
  • fungi such as Aspergillus sp.
  • non-human mammalian sources such as, for example, bovine sp. from which the gene encoding the carbonyl hydrolase chymosin can be obtained.
  • non-human carbonyl hydrolase as used herein has a functional definition which refers to carbonyl
  • a “carbonyl hydrolase variant” has an amino acid sequence which is derived from the amino acid sequence of a “precursor carbonyl hydrolase.”
  • the precursor carbonyl hydrolases (such as a
  • subtilisin include naturally-occurring carbonyl hydrolases
  • 76/103/104/126 76/103/104/107; 76/103/104/210; 76/103/104/126/265 and/or 76/103/104/222; and most preferably are 76/99; 76/104;
  • amino acid position numbers refer to those assigned to the mature Bacillus amyloliquefaciens subtilisin sequence presented in Fig. 1.
  • the invention is not limited to the mutation of this particular subtilisin but extends to precursor carbonyl hydrolases containing amino acid residues at positions which are "equivalent" to the particular identified residues in Bacillus amyloliquefaciens subtilisin.
  • the precursor subtilisin is Bacillus lentus subtilisin and the substitutions, deletions or insertions are made at the equivalent amino acid residue in B.
  • a residue (amino acid) of a precursor carbonyl hydrolase is
  • Bacillus amyloliquefaciens subtilisin equivalent to a residue of Bacillus amyloliquefaciens subtilisin if it is either homologous (i.e., corresponding in position in either primary or tertiary structure) or analogous to a specific residue or portion of that residue in Bacillus amyloliquefaciens subtilisin (i.e., having the same or similar functional capacity to combine, react, or interact chemically).
  • amino acid sequence of a precursor carbonyl hydrolase is directly compared to the Bacillus amyloliquefaciens subtilisin primary sequence and particularly to a set of residues known to be invariant in
  • subtilisins for which sequence is known.
  • Fig. 2 herein shows the conserved residues as between B . amyloliquefaciens subtilisin and B. lentus subtilisin. After aligning the conserved residues, allowing for necessary insertions and deletions in order to maintain
  • subtilisin from Bacillus amyloliquefaciens, Bacillus subtilis, Bacillus
  • licheniformis carlsbergensis
  • Bacillus lentus are aligned to provide the maximum amount of homology between amino acid sequences. A comparison of these sequences shows that there are a number of conserved residues contained in each sequence. These conserved residues (as between BPN' and B. lentus) are identified in Fig. 2.
  • subtilisin from Bacillus lentus PCT Publication No. W089/06279 published July 13, 1989
  • the preferred subtilisin precursor enzyme herein or the subtilisin referred to as PB92 (EP 0 328 299), which is highly homologous to the preferred Bacillus lentus subtilisin.
  • the amino acid sequences of certain of these subtilisins are aligned in Figs. 3A and 3B with the sequence of Bacillus amyloliquefaciens subtilisin to produce the maximum homology of conserved residues. As can be seen, there are a number of deletions in the sequence of Bacillus lentus as compared to Bacillus amyloliquefaciens
  • subtilisin the equivalent amino acid for Vall65 in Bacillus amyloliquefaciens subtilisin in the other subtilisins is isoleucine for B . lentus and B . licheniformis .
  • the amino acid at position +76 is asparagine (N) in both B . amyloliquefaciens and B . lentus subtilisins.
  • N asparagine
  • B . amyloliquefaciens and B . lentus subtilisins the amino acid equivalent to +76 in Bacillus amyloliquefaciens subtilisin is substituted with aspartate (D).
  • D aspartate
  • Equivalent residues may also be defined by determining homology at the level of tertiary structure for a precursor carbonyl hydrolase whose tertiary structure has been determined by x-ray
  • Crystallography Equivalent residues are defined as those for which the atomic coordinates of two or more of the main chain atoms of a particular amino acid residue of the precursor carbonyl hydrolase and Bacillus amyloliquefaciens subtilisin (N on N, CA on CA, C on C and O on O) are within 0.13nm and preferably 0.1nm after alignment. Alignment is achieved after the best model has been oriented and positioned to give the maximum overlap of atomic coordinates of non- hydrogen protein atoms of the carbonyl hydrolase in question to the Bacillus amyloliquefaciens subtilisin. The best model is the crystallographic model giving the lowest R factor for experimental diffraction data at the highest resolution available.
  • Equivalent residues which are functionally analogous to a specific residue of Bacillus amyloliquefaciens subtilisin are defined as those amino acids of the precursor carbonyl hydrolases which may adopt a conformation such that they either alter, modify or
  • Bacillus amyloliquefaciens subtilisin contribute to protein structure, substrate binding or catalysis in a manner defined and attributed to a specific residue of the Bacillus amyloliquefaciens subtilisin. Further, they are those residues of the precursor carbonyl hydrolase (for which a tertiary structure has been obtained by x-ray crystallography) which occupy an analogous position to the extent that, although the main chain atoms of the given residue may not satisfy the criteria of equivalence on the basis of occupying a homologous position, the atomic coordinates of at least two of the side chain atoms of the residue lie with 0.13nm of the corresponding side chain atoms of Bacillus amyloliquefaciens subtilisin.
  • the coordinates of the three dimensional structure of Bacillus amyloliquefaciens subtilisin are set forth in EPO
  • residues identified for substitution, insertion or deletion are conserved residues whereas others are not.
  • residues which are not conserved the replacement of one or more amino acids is limited to substitutions which produce a variant which has an amino acid sequence that does not correspond to one found in nature.
  • conserved residues such as
  • the carbonyl hydrolase variants of the present invention include the mature forms of carbonyl hydrolase variants, as well as the pro- and prepro-forms of such hydrolase variants.
  • the prepro-forms are the preferred construction since this facilitates the expression, secretion and maturation of the carbonyl hydrolase variants.
  • Protein refers to a sequence of amino acids bound to the N-terminal portion of the mature form of a carbonyl hydrolase which when removed results in the appearance of the "mature” form of the carbonyl hydrolase.
  • Many proteolytic enzymes are found in nature as translational proenzyme products and, in the absence of post-translational processing, are expressed in this fashion.
  • prosequence for producing carbonyl hydrolase variants is the putative prosequence of Bacillus amyloliquefaciens subtilisin, although other subtilisin prosequences may be used.
  • subtilisin variants is the putative prosequence of Bacillus amyloliquefaciens subtilisin, although other subtilisin prosequences may be used.
  • Examples 1 and 2 the putative prosequence of Bacillus amyloliquefaciens subtilisin, although other subtilisin prosequences may be used.
  • a “signal sequence” or “presequence” refers to any sequence of amino acids bound to the N-terminal portion of a carbonyl hydrolase or to the N-terminal portion of a prohydrolase which may participate in the secretion of the mature or pro forms of the hydrolase.
  • This definition of signal sequence is a functional one, meant to include all those amino acid sequences encoded by the N-terminal portion of the subtilisin gene or other secretable carbonyl hydrolases which participate in the effectuation of the secretion of subtilisin or other carbonyl hydrolases under native conditions.
  • the present invention utilizes such sequences to effect the secretion of the carbonyl hydrolase variants as defined herein.
  • a preferred signal sequence used in the Examples comprises the first seven amino acid residues of the signal sequence from Bacillus subtilis subtilisin fused to the remainder of the signal sequence of the subtilisin from Bacillus lentus (ATCC 21536).
  • a “prepro” form of a carbonyl hydrolase variant consists of the mature form of the hydrolase having a prosequence operably linked to the amino terminus of the hydrolase and a "pre” or “signal” sequence operably linked to the amino terminus of the prosequence.
  • “Expression vector” refers to a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of said DNA in a suitable host.
  • control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites and sequences which control termination of transcription and translation.
  • the vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. In the present specification, "plasmid” and “vector” are sometimes used
  • the plasmid is the most commonly used form of vector at present.
  • the invention is intended to include such other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.
  • the "host cells” used in the present invention generally are procaryotic or eucaryotic hosts which preferably have been
  • subtilisin A preferred host cell for expressing subtilisin is the Bacillus strain BG2036 which is deficient in enzymatically active neutral protease and alkaline protease (subtilisin).
  • the construction of strain BG2036 is described in detail in US Patent 5,264,366.
  • Other host cells for expressing subtilisin include Bacillus subtilis 1168 (also described in US Patent 4,760,025 (RE 34,606) and US Patent 5,264,366, the disclosure of which are incorporated herein by reference), as well as any suitable Bacillus strain such as B. licheniformis, B. lentus , etc.
  • Host cells are transformed or transfected with vectors constructed using recombinant DNA techniques. Such transformed host cells are capable of either replicating vectors encoding the carbonyl
  • expressed are typically secreted from the host cell into the host cell medium.
  • operably linked when describing the relationship between two DNA regions, simply means that they are functionally related to each other.
  • a presequence is operably linked to a peptide if it functions as a signal sequence, participating in the secretion of the mature form of the protein most probably involving cleavage of the signal sequence.
  • a promoter is operably linked to a coding sequence if it controls the transcription of the sequence;
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.
  • the genes encoding the naturally-occurring precursor carbonyl hydrolase may be obtained in accord with the general methods known to those skilled in the art .
  • the methods generally comprise synthesizing labeled probes having putative sequences encoding regions of the hydrolase of interest, preparing genomic libraries from organisms expressing the hydrolase, and screening the libraries for the gene of interest by hybridization to the probes. Positively hybridizing clones are then mapped and sequenced.
  • the B. lentu ⁇ gene used in the Examples was cloned as described in Example 1 of US Patent 5,185,258, the disclosure of which is incorporated herein.
  • the BPN' gene used in Example 5 was cloned as described in Example 1 in RE 34,606, the disclosure of which is incorporated herein.
  • the cloned carbonyl hydrolase is then used to transform a host cell in order to express the hydrolase.
  • the hydrolase gene is then ligated into a high copy number plasmid. This plasmid replicates in hosts in the sense that it contains the well-known elements
  • a promoter operably linked to the gene in question (which may be supplied as the gene's own homologous promotor if it is recognized, i.e., transcribed, by the host) , a transcription termination and polyadenylation region
  • a selection gene such as an
  • cassette mutagenesis method may be used to facilitate the construction and identification of the carbonyl hydrolase variants of the present invention, although other methods including site-directed mutagenesis may be used.
  • the naturally- occurring gene encoding the hydrolase is obtained and seguenced in whole or in part. Then the sequence is scanned for a point at which it is desired to make a mutation (deletion, insertion or
  • restriction sites are preferably unique sites within the hydrolase gene so as to facilitate the replacement of the gene segment.
  • any convenient restriction site which is not overly redundant in the hydrolase gene may be used, provided the gene fragments generated by restriction digestion can be reassembled in proper sequence. If restriction sites are not present at locations within a convenient distance from the selected point (from 10 to 15 nucleotides) , such sites are generated by substituting nucleotides in the gene in such a fashion that neither the reading frame nor the amino acids encoded are changed in the final
  • the restriction sites flanking the positions to be mutated are digested with the cognate restriction enzymes and a plurality of end termini-complementary oligonucleotide cassettes are ligated into the gene.
  • the mutagenesis is simplified by this method because all of the oligonucleotides can be synthesized so as to have the same
  • restriction sites and no synthetic linkers are necessary to create the restriction sites.
  • proteolytic activity is defined as the rate of hydrolysis of peptide bonds per milligram of active enzyme. Many well known procedures exist for measuring proteolytic activity (K. M. Kalisz, "Microbial Proteinases, " Advances in Biochemical
  • the variant enzymes of the present invention may have other modified properties such as K m , k cat , k cat /K m ratio and/or modified substrate specificity and/or modified pH activity profile. These enzymes can be tailored for the particular substrate which is anticipated to be present, for example, in the preparation of peptides or for hydrolytic processes such as laundry uses.
  • the objective is to secure a variant carbonyl hydrolase having altered proteolytic activity as compared to the precursor carbonyl hydrolase, since increasing such activity (numerically larger) enables the use of the enzyme to more
  • subtilisin a subtilisin.
  • lower proteolytic activity may be desirable, for example a decrease in proteolytic activity would be useful where the synthetic activity of the carbonyl hydrolases is desired (as for synthesizing peptides). One may wish to decrease this proteolytic activity, which is capable of destroying the product of such synthesis. Conversely, in some instances it may be desirable to increase the proteolytic activity of the variant enzyme versus its precursor. Additionally, increases or decreases (alteration) of the stability of the variant, whether alkaline or thermal stability, may be desirable. Increases or decreases in k cat , K m or k cat /K m are specific to the substrate used to determine these kinetic parameters.
  • Aspartate (D) in the preferred embodiment in combination with modification of one or more of the following amino acid residues +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274, to produce enhanced stability and/or enhanced activity of the resulting mutant enzyme.
  • N76D/S103A/V104I N76D/V104I/I107V; N76D/V104Y/I107V and
  • N76D/S101R/S103A/V104I are also described in the Examples. These substitutions are preferably made in Bacillus lentus (recombinant or native-type) subtilisin, although the substitutions may be made in any Bacillus subtilisin.
  • compositions comprising the carbonyl hydrolase mutants of the invention.
  • suitable surfactants useful in compositions comprising the carbonyl hydrolase mutants of the invention. These include nonionic, anionic, cationic, anionic or zwitterionic detergents, as disclosed in US 4,404,128 to Barry J. Anderson and US 4,261,868 to Jiri Flora, et al.
  • a suitable surfactants include nonionic, anionic, cationic, anionic or zwitterionic detergents, as disclosed in US 4,404,128 to Barry J. Anderson and US 4,261,868 to Jiri Flora, et al.
  • detergent formulation is that described in Example 7 of US Patent 5,204,015 (previously incorporated by reference).
  • the art is familiar with the different formulations which can be used as cleaning compositions. In addition to typical cleaning
  • subtilisin variants of the present invention may be used for any purpose that native or wild-type subtilisins are used.
  • these variants can be used, for example, in bar or liquid soap applications, dishcare
  • the variants of the present invention may comprise enhanced performance in a detergent composition (as compared to the precursor) .
  • enhanced performance in a detergent is defined as increasing cleaning of certain enzyme sensitive stains such as grass or blood, as determined by usual evaluation after a standard wash cycle.
  • Subtilisins of the invention can be formulated into known powdered and liquid detergents having pH between 6.5 and 12.0 at levels of about .01 to about 5% (preferably .1% to .5%) by weight.
  • These detergent cleaning compositions can also include other enzymes such as known proteases, amylases, cellulases, lipases or
  • subtilisins of the invention can be used in a cleaning composition without
  • detergents again either alone or in combination with builders and stabilizers.
  • the cloning and the construction for expression of the subtilisin gene from B . lentus was performed essentially the same as that described in US Patent 5,185,258.
  • the plasmid GGA274 (described in Fig. 4 herein) was further modified in the following manner, as shown in Fig. 5.
  • the PstI site that was introduced during the construction of the GGA274 plasmid was removed by the
  • oligonucleotide directed mutagenesis described below, with an oligonucleotide having the following sequence: 5'
  • GAAGCTGCAACTCGTTAAA 3' (Seq. ID No.1).
  • the underlined "A" residue eliminated the recognition sequence of restriction enzyme PstI and changed the corresponding amino acid residue from alanine to threonine at position 274.
  • Threonine at position 274 is the wild-type residue originally found in the cloned B .
  • lentus subtilisin gene sequences The DNA segment encoding subtilisin was excised from the plasmid GGA274 or its derivatives (GGT274 shown in Fig. 5) by EcoRI and BamHI digest. The DNA fragment was subcloned back into Bacteriophage M13 -based vectors, such as MP19, for mutagenesis.
  • Oligonucleotide-directed mutagenesis was performed as described in Zoller, M., et al. (1983), Methods Enzymol., 100:468-500.
  • a synthetic oligonucleotide of the sequence 5' GCTGCTCTAGACAATTCG 3' (Seq. ID No.2) was used to change the amino acid residue at position 76 from asparagine (N) to aspartic acid (D), or N76D.
  • the underlined "G” and "C” residues denote changes from the wild-type gene sequence.
  • the CA keeps the leucine at position +75 and changes the amino acid sequence to introduce an XbaI recognition site of the XbaI restriction enzyme (TCTAGA), while the change at GAC changes asparagine at +76 to aspartate.
  • TCTAGA XbaI recognition site of the XbaI restriction enzyme
  • oligonucleotide for mutagenesis at positions 99, 101, 103 and 104, different oligonucleotides can be used depending on the combination of mutations desired.
  • an oligonucleotide of the sequence 5' GTATTAGGGGCGGACGGTCGAGGCGCCATCAGCTCGATT 3' (Seq. ID No .3 ) was used to simultaneously make the following changes: S99D; S101R; S103A and V104I in a single subtilisin molecule.
  • CACGTTGCTAGCTTGAGTTTAG 3' (Seq. ID No.5) were utilized to generate I107V and N123S, respectively. Again, the underlined residues denote changes from wild-type sequences which produced desired changes either in amino acid sequences or restriction enzyme recognition sequences.
  • subtilisin variant stock solution was added to a 1 cm cuvette containing substrate dissolved in 0.1M Tris-HCL buffer, pH 8.6, and
  • N76D/V104Y/I107V and N76D/S101R/S103A/V104I are significantly more stable than the single substitution variant N76D in the test condition without 50mM CaCl 2 added.
  • the mutagenesis protocol was essentially the same as described above in Example 2.
  • the single-stranded DNA template was generated by phagemid method.
  • To construct the phagemid vector for generating the single-stranded DNA template we first constructed the vector pBCDAICAT. The flow chart of vector construction is outlined in Figure 8. First, the ClaI to ClaI fragment encoding the CAT gene from pC194 plasmid (Horinouchi, S. and Weisblum, B., J.
  • Bacteriol., 150:8-15, 1982 was cloned into the Accl site of polylinker region of pUC19 (New England BioLabs, Beverly, MA) to make plasmid pUCCHL and the EcoRI-Dral 0.6 KB fragment from the 5' end of the GG36DAI encoding DNA was cloned into the EcoRI and EcoRV sites of pBSKS plasmid (Stratagene, Inc., San Diego, CA) to make pBC2SK5.
  • the single EcoRI site of the plasmid pBC2SK5 was eliminated by EcoRI digestion, followed by filling in catalyzed-by-T4 DNA polymerase, and religation to generate the plasmid pBC2SK-5R which does not have the EcoRI site.
  • the EcoRI-Dral fragment which was cloned into pBCSK-5R was isolated as a PstI-HindIII fragment and cloned into the PstI-HindIII site of the pUCCHL (part of the polylinker of pUC19) to generate plasmid pUCCHL5R.
  • GG36DAI gene The encoding sequence of GG36DAI gene was excised as an EcoRI-BamHI fragment and cloned into the EcoRI-BamHI sites of pUCCHL5R to make pUCCAT.
  • the large EcoRI-HindIII fragment of pUCCAT was then cloned into the EcoRI and HindIII sites of BS2KS+ to generate the plasmid pBCDAICAT.
  • E. coli-containing pBCDAICAT were infected with phage R408 (obtained from Stratagene, San Diego, CA) following the protocol described in Russel, M., Kidd, S. and Kelley, M.R., GENE 45:333-338, 1986.
  • phage R408 obtained from Stratagene, San Diego, CA
  • BPN' amyloliquefaciens
  • N76D/Q103A/Y104I/Y217L was done in a similar fashion except in two consecutive steps. N76D was first introduced into BPN' Y217L to make BPN' N76D/Y217L and a second mutagenesis was done to convert BPN' N76D/Y217L to BPN' N76D/Q103A/Y104I/Y217L.
  • BPN' N76D/Q103A/Y104I/Y217L All steps involved in the cloning, the single-stranded DNA preparation, the mutagenesis, and the screening for mutants were carried out as described above. Expression of the BPN' gene and its variants were achieved by integrating plasmid DNA (pBCFNACAT containing the different
  • Purified enzyme was buffer-exchanged into 0.1 M glycine pH 10.0, 0.01% Tween-80 by applying the enzyme to a column consisting of Sephadex G-25 equilibrated with this buffer and eluting the enzyme from the column using the same buffer.
  • Half-life which is the length of time required for 50% enzyme inactivation, was determined from the first-order plot of reaction velocity as a function of the time of incubation at 60°C.
  • BPN' amyloliquefaciens subtilisin 50 0.14 3.60E+05
  • N76D/S103A/V104I/L126I 410 N76D/S103A/V104I/L126V 320
  • wash performance of the variants described in the previous examples was evaluated by measuring the removal of stain from EMPA 116 (blood/milk/carbon black on cotton) cloth swatches (Testfabrics, Inc., Middlesex, NJ 07030).
  • Sodium perborate monohydrate was obtained from Degussa Corporation, Ridgefield-Park, NJ 07660.
  • Sokalan CP5 was obtained from BASF Corporation, Parsippany, NJ 07054.
  • Tinopal AMS GX was obtained from Ciba-Geigy Corporation, Greensboro, NC 27419.
  • Protease Stability in a Liquid Detergent Formulation A comparison of protease stability toward inactivation in a liquid detergent formulation was made for Bacillus lentus subtilisin and it's variant enzyme N76D/S103A/V104I according to the procedure outlined herein.
  • the detergent formulation used for the study was a commercially purchased bottle of Tide Ultra liquid lanudry detergent made in the USA by Procter & Gamble Company. Heat treatment of the detergent formulation was necessary to inactivate in-situ protease. This was accomplished by incubating the detergent at 96°C for a period of 4.5 hours. Concentrated preparations of the B . lentus subtilisin and N76D/S103A/V104I variant, in the range of 20
  • N76D/S103A/V104I variant was observed to have significantly greater stability towards inactivation than the native B. lentus enzyme.
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • GGTCTACTAA AATATTATTC CATACTATAC AATTAATACA CAGAATAATC TGTCTATTGG 60
  • MOLECULE TYPE DNA (genomic)
  • CAAAAGAACC CATCTTGGTC CAATGTACAA ATCCGCAATC ATCTAAAGAA TACGGCAACG 1080
  • MOLECULE TYPE DNA (genomic)
  • xi SEQUENCE DESCRIPTION: SEQ ID NO:12:
  • CAAAAGAACC CATCTTGGTC CAATGTACAA ATCCGCAATC ATCTAAAGAA TACGGCAACG 1080
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)

Abstract

Novel carbonyl hydrolase variants derived from the DNA sequences of naturally-occuring or recombinant non-human carbonyl hydrolases are disclosed. The variant carbonyl hydrolases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant carbonyl hydrolase to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor carbonyl hydrolase. Such variant carbonyl hydrolases have properties which are different from those of the precursor hydrolase, such as altered proteolytic activity, altered stability, etc. The substituted amino acid residues correspond to positions +76 in combination with one or more of the folloqing residues +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 in Bacillus amyloliquefaciens subtilisin.

Description

SUBTILISIN VARIANTS
Cross-Reference to Related Applications
This application is a continuation-in-part of US Application Serial Number 08/137,240 filed October 14, 1993 (pending) and which is incorporated herein by reference in its entirety.
Field of the Invention
The present invention relates to novel carbonyl hydrolase variants having an amino acid sequence wherein a plurality of amino acid residues of a precursor carbonyl hydrolase, specifically those at positions corresponding or equivalent to residue +76 in combination with one or more of the residues selected from the group consisting of +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 in Bacillus amyloliquefaciens
subtilisin, have been substituted with a different amino acid. Such mutant/variant carbonyl hydrolases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding a naturally-occurring or recombinant carbonyl hydrolase to encode the
substitution of a plurality of these amino acid residues in a precursor amino acid sequence alone or in combination with other substitution, insertion or deletion in the precursor amino acid sequence.
Background of the Invention
Serine proteases are a subgroup of carbonyl hydrolase. They comprise a diverse class of enzymes having a wide range of
specificities and biological functions. Stroud, R. Sci. Amer., 131:74-88. Despite their functional diversity, the catalytic machinery of serine proteases has been approached by at least two genetically distinct families of enzymes: the subtilisins and the mammalian chymotrypsin related and homologous bacterial serine proteases (e.g., trypsin and S. gresius trypsin). These two families of serine proteases show remarkably similar mechanisms of catalysis. Kraut, J. (1977), Ann. Rev. Biochem., 46:331-358.
Furthermore, although the primary structure is unrelated, the tertiary structure of these two enzyme families bring together a conserved catalytic triad of amino acids consisting of serine, histidine and aspartate. Subtilisin is a serine endoprotease (MW 27,500) which is secreted in large amounts from a wide variety of Bacillus species and other microorganisms. The protein sequence of subtilisin has been determined from at least four different species of Bacillus .
Markland, F.S., et al. (1983), Honne-Seyler's Z. Physiol. Chem., 364:1537-1540. The three-dimensional crystallographic structure of Bacillus amyloliquefaciens subtilisin to 2.5A resolution has also been reported. Wright, C.S., et al. (1969), Nature, 221:235-242; Drenth, J., et al. (1972), Eur. J. Biochem., 26:177-181. These studies indicate that although subtilisin is genetically unrelated to the mammalian serine proteases, it has a similar active site structure. The x-ray crystal structures of subtilisin containing covalently bound peptide inhibitors (Robertus, J.D., et al. (1972), Biochemistry, 11:2439-2449) or product complexes (Robertus, J.D., et al. (1976), J. Biol. Chem., 251:1097-1103) have also provided information regarding the active site and putative substrate binding cleft of subtilisin. In addition, a large number of kinetic and chemical modification studies have been reported for subtilisin (Philipp, M., et al. (1983), Mol. Cell. Biochem., 51:5-32; Svendsen, B. (1976), Carlsberg Res. Comm., 41:237-291; Markland, F.S. Id.) as well as at least one report wherein the side chain of methionine at residue 222 of subtilisin was converted by hydrogen peroxide to methionine-sulfoxide (Stauffer, D.C., et al. (1965), J. Biol. Chem., 244:5333-5338) and the side chain of serine at residue 221 converted to cysteine by chemical modification (Polgar, et al. (1981),
Biochimica et Biophysica Acta, 667:351-354.)
US Patent 4,760,025 (RE 34,606) discloses the modification of subtilisin amino acid residues corresponding to positions in
Bacillus amyloliquefaciens subtilisin tyrosine -1, aspartate +32, asparagine +155, tyrosine +104, methionine +222, glycine +166, histidine +64, glycine +169, phenylalanine +189, serine +33, serine +221, tyrosine +217, glutamate +156 and alanine +152. US Patent 5,182,204 discloses the modification of the amino acid +224 residue in Bacillus amyloliquefaciens subtilisin and equivalent positions in other subtilisins which may be modified by way of substitution, insertion or deletion and which may be combined with modifications to the residues identified in US Patent 4,760,025 (RE 34,606) to form useful subtilisin mutants or variants. US Patent 5,155,033 discloses similar mutant subtilisins having a modification at an equivalent position to +225 of B . amyloliquefaciens subtilisin. US Patents 5,185,258 and 5,204,015 disclose mutant subtilisins having a modification at positions +123 and/or +274. The disclosure of these patents is incorporated herein by reference, as is the disclosure of US Patent Application SN 07/898,382, which discloses the
modification of many amino acid residues within subtilisin,
including specifically +99, +101, +103, +107, +126, +128, +135, +197 and +204. All of these patents/applications are commonly owned. US Patent 4,914,031 discloses certain subtilisin analogs, including a subtilisin modified at position +76. The disclosure of this patent is also incorporated herein by reference. The particular residues identified herein and/or the specific combinations claimed herein, however, are not identified in these references.
Accordingly, it is an object herein to provide carbonyl hydrolase (preferably subtilisin) variants containing the substitution of a plurality of amino acid residues in the DNA encoding a precursor carbonyl hydrolase corresponding to positions +76 in combination with one or more positions selected from the group +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 in Bacillus amyloliquefaciens subtilisin. Such variants generally have at least one property which is different from the same property of the carbonyl hydrolase precursor from which the amino acid sequence of said variant is derived.
It is a further object to provide DNA sequences encoding such carbonyl hydrolase variants, as well as expression vectors
containing such variant DNA sequences.
Still further, another object of the invention is to provide host cells transformed with such vectors, as well as host cells which are capable of expressing such DNA to produce carbonyl hydrolase variants either intracellularly or extracellularly.
The references discussed above are provided solely for their disclosure prior to the filing date of the instant case, and nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of a prior invention or priority based on earlier filed applications. Summary of the Invention
The invention includes non-naturally-occurring carbonyl hydrolase variants having a different proteolytic activity, stability, substrate specificity, pH profile and/or performance characteristic as compared to the precursor carbonyl hydrolase from which the amino acid sequence of the variant is derived. The precursor carbonyl hydrolase may be a naturally-occurring carbonyl hydrolase or recombinant hydrolase. Specifically, such carbonyl hydrolase variants have an amino acid sequence not found in nature, which is derived by replacement of a plurality of amino acid residues of a precursor carbonyl hydrolase with different amino acids. The plurality of amino acid residues of the precursor enzyme correspond to position +76 in combination with one or more of the following residues +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274, where the numbered position corresponds to naturally-occurring subtilisin from Bacillus
amyloliquefaciens or to equivalent amino acid residues in other carbonyl hydrolases or subtilisins, such as Bacillus lentus
subtilisin. The carbonyl hydrolase variants of the present
invention comprise replacement of amino acid residue +76 in
combination with one or more additional modifications. Preferably the variant enzymes of the present invention comprise the
substitution, deletion or insertion of amino acid residues in the following combinations: 76/99; 76/101; 76/103; 76/104; 76/107;
76/123; 76/99/101; 76/99/103; 76/99/104; 76/101/103; 76/101/104; 76/103/104; 76/104/107; 76/104/123; 76/107/123; 76/99/101/103;
76/99/101/104; 76/99/103/104; 76/101/103/104; 76/103/104/123;
76/104/107/123; 76/99/101/103/104; 76/99/103/104/123;
76/99/101/103/104/123; 76/103/104/128; 76/103/104/260;
76/103/104/265; 76/103/104/197; 76/103/104/105; 76/103/104/135;
76/103/104/126; 76/103/104/107; 76/103/104/210; 76/103/104/126/265 and/or 76/103/104/222. Most preferably the variant enzymes of the present invention comprise the substitution, deletion or insertion of an amino acid residue in the following combination of residues: 76/99; 76/104; 76/99/104; 76/103/104; 76/104/107; 76/101/103/104; 76/99/101/103/104 and 76/101/104 of B . amyloliquefaciens subtilisin.
The invention also includes variant DNA sequences encoding such carbonyl hydrolase or subtilisin variants. These variant DNA sequences are derived from a precursor DNA sequence which encodes a naturally-occurring or recombinant precursor enzyme. The variant DNA sequences are derived by modifying the precursor DNA sequence to encode the substitution of one or more specific amino acid residues encoded by the precursor DNA sequence corresponding to positions 76, 99, 101, 103, 104, 107, 123, 27, 105, 109, 126, 128, 135, 156, 166, 195, 197, 204, 206, 210, 216, 217, 218, 222, 260, 265 and/or 274 in Bacillus amyloliquefaciens or any combination thereof. Although the amino acid residues identified for modification herein are
identified according to the numbering applicable to B.
amyloliquefaciens (which has become the conventional method for identifying residue positions in all subtilisins), the preferred precursor DNA sequence useful in the present invention is the DNA sequence of Bacillus lentus as shown in Fig. 6 (Seq ID No.11).
The variant DNA sequences of the present invention encode the insertion or substitution of the amino acid residue 76 in
combination with one or more additional modification. Preferably the variant DNA sequences encode the substitution or insertion of amino acid residues in the following combinations: 76/99; 76/101; 76/103; 76/104; 76/107; 76/123; 76/99/101; 76/99/103; 76/99/104; 76/101/103; 76/101/104; 76/103/104; 76/104/107; 76/104/123;
76/107/123; 76/99/101/103; 76/99/101/104; 76/99/103/104;
76/101/103/104; 76/103/104/123; 76/104/107/123; 76/99/101/103/104; 76/99/103/104/123; 76/99/101/103/104/123; 76/103/104/128;
76/103/104/260; 76/103/104/265; 76/103/104/197; 76/103/104/105;
76/103/104/135; 76/103/104/126; 76/103/104/107; 76/103/104/210;
76/103/104/126/265 and/or 76/103/104/222. Most preferably the variant DNA sequences encode for the modification of the following combinations of residues: 76/99; 76/104; 76/99/104; 76/103/104; 76/104/107; 76/101/103/104; 76/99/101/103/104 and 76/101/104. These recombinant DNA sequences encode carbonyl hydrolase variants having a novel amino acid sequence and, in general, at least one property which is substantially different from the same property of the enzyme encoded by the precursor carbonyl hydrolase DNA sequence. Such properties include proteolytic activity, substrate specificity, stability, altered pH profile and/or enhanced performance
characteristics.
The present invention encompasses the substitution of any of the nineteen naturally occurring L-amino acids at the designated amino acid residue positions. Such substitutions can be made in any precursor subtilisin (procaryotic, eucaryotic, mammalian, etc.). Preferably, the substitution to be made at each of the identified amino acid residue positions include but are not limited to:
substitutions at position 76 including D, H, E, G, F, K, P and N; substitutions at position 99 including D, T, N, Q, G and S;
substitutions at position 101 including G, D, K, L, A, E, S and R; substitutions at position 103 including Q, T, D, E, Y, K, G, R, S and A; substitutions at position 104 including all nineteen
naturally-occurring amino acids; substitutions at position 107 including V, L, M, Y, G, E, F, T, S, A, N and I; substitutions at position 123 including N, T, I, G, A, C and S; substitutions at position 27 including K, N, C, V and T; substitutions at position 105 including A, D, G, R and N; substitutions at position 107 including A, L, V, Y, G, F, T, S and A; substitutions at position 109 including S, K, R, A, N and D; substitutions at position 126 including A, F, I, V and G; substitutions at position 128 including G, L and A; substitutions at position 135 including A, F, I, S and V; substitutions at position 156 including D, E, A, G, Q and K;
substitutions at position 166 including all nineteen naturally-occurring amino acids; substitutions at position 195 including E; substitutions at position 197 including E; substitutions at position 204 including A, G, C, S and D; substitutions at position 206 including L, Y, N, D and E; substitutions at position 210 including L, I, S, C and F; substitutions at position 216 including V, E, T and K; substitutions at position 217 including all nineteen
naturally-occurring amino acids; substitutions at position 218 including S, A, G, T and V; substitutions at position 222 including all nineteen naturally-occurring amino acids; substitutions at position 260 including P, N, G, A, S, C, K and D; substitutions at position 265 including N, G, A, S, C, K, Y and H; and substitutions at position 274 including A and S. The specifically preferred amino acid(s) to be substituted at each such position are designated below in Table I. Although specific amino acids are shown in Table I, it should be understood that any amino acid may be substituted at the identified residues. Table I
Amino Acid Preferred Amino Acid to
Residue be Substituted/Inserted
+76 D,H
+99 D,T,N,G
+101 R,G,D,K,L,A,E
+103 A,Q,T,D,E,Y,K,G,R
+104 I,Y,S,L,A,T,G,F,M,W,D,V,N
+107 V,L,Y,G,F,T,S,A,N
+123 S,T,I
+27 K
+105 A,D,
+109 S,K,R
+126 A,I,V,F
+128 G,L
+135 I,A,S
+156 E,D,Q
+166 D,G,E,K,N,A,F,I,V,L
+195 E
+197 E
+204 A,G,C
+206 L
+210 I,S,C
+216 V
+217 H,I,Y,C,A,G,F,S,N,E,K
+218 S
+222 A,Q,S,C,I,K
+260 P,A,S,N,G
+265 N,A,G,S
+274 A,S
Further, the invention includes expression vectors containing such variant carbonyl hydrolase DNA sequences, as well as host cells transformed with such vectors which are capable of producing such variants. The invention also relates to detergent compositions comprising the carbonyl hydrolase variants of the invention.
Brief Description of the Drawings
Figs. 1 A-C depict the DNA and amino acid sequence for Bacillus amyloliquefaciens subtilisin and a partial restriction map of this gene (Seq. ID No.6).
Fig. 2 depicts the conserved amino acid residues among subtilisins from Bacillus amyloliquefaciens (BPN)' and Bacillus lentus (wild-type).
Figs. 3A and 3B depict the amino acid sequence of four subtilisins. The top line represents the amino acid sequence of subtilisin from Bacillus amyloliquefaciens subtilisin (also sometimes referred to as subtilisin BPN') (Seq. ID No.7). The second line depicts the amino acid sequence of subtilisin from Bacillus subtilis (Seq. ID No.8). The third line depicts the amino acid sequence of subtilisin from B. licheniformis (Seq. ID No.9). The fourth line depicts the amino acid sequence of subtilisin from Bacillus lentus (also referred to as subtilisin 309 in PCT WO89/06276) (Seq. ID No.10). The symbol * denotes the absence of specific amino acid residues as compared to subtilisin BPN'.
Fig. 4 depicts the construction of plasmid GGA274.
Fig. 5 depicts the construction of GGT274 which is an intermediate to certain expression plasmids used in this application.
Figs. 6A and 6B depict the DNA and amino acid sequence of subtilisin from Bacillus lentus (Seq. ID No.11). The mature subtilisin protein is coded by the codons beginning at the codon GCG (334-336)
corresponding to Ala.
Figs. 7A and 7B depict the DNA and amino acid sequence of a
preferred embodiment of the invention (N76D/S103A/V104I) (Seq. ID No.12). The DNA in this figure has been modified by the methods described to encode aspartate at position 76, alanine at position 103 and isoleucine at position 104. The mature subtilisin variant protein is coded by the codons beginning at the codon GCG (334-336) corresponding to Ala.
Fig. 8 depicts the construction of vector pBCDAICAT.
Fig. 9 depicts the construction of vector pUCCATFNA.
Fig. 10 shows the stability of a preferred mutant enzyme compared to wild-type, in a liquid detergent formulation.
Detailed Description of the Invention
It has been discovered that in vitro mutations in B. lentus
subtilisin at an amino acid residue equivalent to +76 in Bacillus amyloliquefaciens subtilisin produces subtilisin variants exhibiting altered stability (e.g., modified autoproteolytic stability) over precursor subtilisins. (See Tables IV and VI.) It has also been discovered that in vitro mutation at residues equivalent to +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 in Bacillus
amyloliquefaciens subtilisin, alone or in combination with each other and in any combination with +76 mutations, produce subtilisin variants exhibiting altered proteolytic activity, altered thermal stability, altered pH profile, altered substrate specificity and/or altered performance characteristics.
Carbonyl hydrolases are enzymes which hydrolyze compounds containing
Figure imgf000011_0001
bonds in which X is oxygen or nitrogen. They include naturally-occurring carbonyl hydrolases and recombinant carbonyl hydrolases. Naturally-occurring carbonyl hydrolases principally include
hydrolases, e.g., peptide hydrolases such as subtilisins or
metalloproteases. Peptide hydrolases include α-aminoacylpeptide hydrolase, peptidylamino acid hydrolase, acylamino hydrolase, serine carboxypeptidase, metallocarboxypeptidase, thiol proteinase, carboxylproteinase and metalloproteinase. Serine, metallo, thiol and acid proteases are included, as well as endo and exo-proteases .
"Recombinant carbonyl hydrolase" refers to a carbonyl hydrolase in which the DNA sequence encoding the naturally-occurring carbonyl hydrolase is modified to produce a mutant DNA sequence which encodes the substitution, insertion or deletion of one or more amino acids in the carbonyl hydrolase amino acid sequence. Suitable
modification methods are disclosed herein, and in US Patent
4,760,025 (RE 34,606), US Patent 5,204,015 and US Patent 5,185,258, the disclosure of which are incorporated herein by reference.
Subtilisins are bacterial or fungal carbonyl hydrolases which generally act to cleave peptide bonds of proteins or peptides. As used herein, "subtilisin" means a naturally-occurring subtilisin or a recombinant subtilisin. A series of naturally-occurring
subtilisins is known to be produced and often secreted by various microbial species. Amino acid sequences of the members of this series are not entirely homologous. However, the subtilisins in this series exhibit the same or similar type of proteolytic activity. This class of serine proteases shares a common amino acid sequence defining a catalytic triad which distinguishes them from the chymotrypsin related class of serine proteases. The subtilisins and chymotrypsin related serine proteases both have a catalytic triad comprising aspartate, histidine and serine. In the subtilisin related proteases the relative order of these amino acids, reading from the amino to carboxy terminus, is aspartate-histidine-serine. In the chymotrypsin related proteases the relative order, however, is histidine-aspartate-serine. Thus, subtilisin herein refers to a serine protease having the catalytic triad of subtilisin related proteases. Examples include but are not limited to the subtilisins identified in Fig. 3 herein.
"Recombinant subtilisin" refers to a subtilisin in which the DNA sequence encoding the subtilisin is modified to produce a variant (or mutant) DNA sequence which encodes the substitution, deletion or insertion of one or more amino acids in the naturally-occurring subtilisin amino acid sequence. Suitable methods to produce such modification, and which may be combined with those disclosed herein, include those disclosed in US Patent 4,760,025 (RE 34,606), US Patent 5,204,015 and US Patent 5,185,258.
"Non-human carbonyl hydrolases" and the DNA encoding them may be obtained from many procaryotic and eucaryotic organisms. Suitable examples of procaryotic organisms include gram negative organisms such as E. coli or Pseudomonas and gram positive bacteria such as Micrococcus or Bacillus . Examples of eucaryotic organisms from which carbonyl hydrolase and their genes may be obtained include yeast such as Saccharomyces cerevisiae, fungi such as Aspergillus sp. and non-human mammalian sources such as, for example, bovine sp. from which the gene encoding the carbonyl hydrolase chymosin can be obtained. As with subtilisins, a series of carbonyl hydrolases can be obtained from various related species which have amino acid sequences which are not entirely homologous between the members of that series but which nevertheless exhibit the same or similar type of biological activity. Thus, non-human carbonyl hydrolase as used herein has a functional definition which refers to carbonyl
hydrolases which are associated, directly or indirectly, with procaryotic and eucaryotic sources. A "carbonyl hydrolase variant" has an amino acid sequence which is derived from the amino acid sequence of a "precursor carbonyl hydrolase." The precursor carbonyl hydrolases (such as a
subtilisin) include naturally-occurring carbonyl hydrolases
(subtilisin) and recombinant carbonyl hydrolases (subtilisin). The amino acid sequence of the carbonyl hydrolase variant is "derived" from the precursor hydrolase amino acid sequence by the
substitution, deletion or insertion of one or more amino acids of the precursor amino acid sequence. Such modification is of the "precursor DNA sequence" which encodes the amino acid sequence of the precursor carbonyl hydrolase (subtilisin) rather than
manipulation of the precursor carbonyl hydrolase (subtilisin) enzyme per se . Suitable methods for such manipulation of the precursor DNA sequence include methods disclosed herein, as well as methods known to those skilled in the art (see, for example, EP 0 328299,
WO89/06279 and the US patents and applications already referenced herein).
Specific residues corresponding to position +76 in combination with one or more of the following positions +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 of Bacillus amyloliquefaciens subtilisin are identified herein for mutation. Preferably the modified residues are selected from the following combinations: 76/99; 76/101; 76/103; 76/104; 76/107;
76/123; 76/99/101; 76/99/103; 76/99/104; 76/101/103; 76/101/104; 76/103/104; 76/104/107; 76/104/123; 76/107/123; 76/99/101/103;
76/99/101/104; 76/99/103/104; 76/101/103/104; 76/103/104/123;
76/104/107/123; 76/99/101/103/104; 76/99/103/104/123;
76/99/101/103/104/123; 76/103/104/128; 76/103/104/260;
76/103/104/265; 76/103/104/197; 76/103/104/105; 76/103/104/135;
76/103/104/126; 76/103/104/107; 76/103/104/210; 76/103/104/126/265 and/or 76/103/104/222; and most preferably are 76/99; 76/104;
76/99/104; 76/103/104; 76/104/107; 76/101/103/104; 76/99/101/103/104 and 76/101/104. These amino acid position numbers refer to those assigned to the mature Bacillus amyloliquefaciens subtilisin sequence presented in Fig. 1. The invention, however, is not limited to the mutation of this particular subtilisin but extends to precursor carbonyl hydrolases containing amino acid residues at positions which are "equivalent" to the particular identified residues in Bacillus amyloliquefaciens subtilisin. In a preferred embodiment of the present invention, the precursor subtilisin is Bacillus lentus subtilisin and the substitutions, deletions or insertions are made at the equivalent amino acid residue in B.
lentus corresponding to those listed above.
A residue (amino acid) of a precursor carbonyl hydrolase is
equivalent to a residue of Bacillus amyloliquefaciens subtilisin if it is either homologous (i.e., corresponding in position in either primary or tertiary structure) or analogous to a specific residue or portion of that residue in Bacillus amyloliquefaciens subtilisin (i.e., having the same or similar functional capacity to combine, react, or interact chemically).
In order to establish homology to primary structure, the amino acid sequence of a precursor carbonyl hydrolase is directly compared to the Bacillus amyloliquefaciens subtilisin primary sequence and particularly to a set of residues known to be invariant in
subtilisins for which sequence is known. Fig. 2 herein shows the conserved residues as between B . amyloliquefaciens subtilisin and B. lentus subtilisin. After aligning the conserved residues, allowing for necessary insertions and deletions in order to maintain
alignment (i.e., avoiding the elimination of conserved residues through arbitrary deletion and insertion), the residues equivalent to particular amino acids in the primary sequence of Bacillus amyloliquefaciens subtilisin are defined. Alignment of conserved residues preferably should conserve 100% of such residues. However, alignment of greater than 75% or as little as 50% of conserved residues is also adequate to define equivalent residues.
Conservation of the catalytic triad, Asp32/His64/Ser221 should be maintained.
For example, in Fig. 3 the amino acid sequence of subtilisin from Bacillus amyloliquefaciens, Bacillus subtilis, Bacillus
licheniformis ( carlsbergensis) and Bacillus lentus are aligned to provide the maximum amount of homology between amino acid sequences. A comparison of these sequences shows that there are a number of conserved residues contained in each sequence. These conserved residues (as between BPN' and B. lentus) are identified in Fig. 2.
These conserved residues, thus, may be used to define the
corresponding equivalent amino acid residues of Bacillus amyloliquefaciens subtilisin in other carbonyl hydrolases such as subtilisin from Bacillus lentus (PCT Publication No. W089/06279 published July 13, 1989), the preferred subtilisin precursor enzyme herein, or the subtilisin referred to as PB92 (EP 0 328 299), which is highly homologous to the preferred Bacillus lentus subtilisin. The amino acid sequences of certain of these subtilisins are aligned in Figs. 3A and 3B with the sequence of Bacillus amyloliquefaciens subtilisin to produce the maximum homology of conserved residues. As can be seen, there are a number of deletions in the sequence of Bacillus lentus as compared to Bacillus amyloliquefaciens
subtilisin. Thus, for example, the equivalent amino acid for Vall65 in Bacillus amyloliquefaciens subtilisin in the other subtilisins is isoleucine for B . lentus and B . licheniformis .
Thus, for example, the amino acid at position +76 is asparagine (N) in both B . amyloliquefaciens and B . lentus subtilisins. In the preferred subtilisin variant of the invention, however, the amino acid equivalent to +76 in Bacillus amyloliquefaciens subtilisin is substituted with aspartate (D). A comparison of certain of the amino acid residues identified herein for substitution versus the most preferred substitution for each such position is provided in Table II for illustrative purposes.
Table II
+76 +99 +101 +103 +104 +107 +123
B . amyloliquefaciens N D s Q Y I N
(wild-type)
B . lentus (wild-type) N S S S V I N
Most Preferred D D R A I/Y V S
Substitution
Equivalent residues may also be defined by determining homology at the level of tertiary structure for a precursor carbonyl hydrolase whose tertiary structure has been determined by x-ray
crystallography. Equivalent residues are defined as those for which the atomic coordinates of two or more of the main chain atoms of a particular amino acid residue of the precursor carbonyl hydrolase and Bacillus amyloliquefaciens subtilisin (N on N, CA on CA, C on C and O on O) are within 0.13nm and preferably 0.1nm after alignment. Alignment is achieved after the best model has been oriented and positioned to give the maximum overlap of atomic coordinates of non- hydrogen protein atoms of the carbonyl hydrolase in question to the Bacillus amyloliquefaciens subtilisin. The best model is the crystallographic model giving the lowest R factor for experimental diffraction data at the highest resolution available.
Figure imgf000016_0001
Equivalent residues which are functionally analogous to a specific residue of Bacillus amyloliquefaciens subtilisin are defined as those amino acids of the precursor carbonyl hydrolases which may adopt a conformation such that they either alter, modify or
contribute to protein structure, substrate binding or catalysis in a manner defined and attributed to a specific residue of the Bacillus amyloliquefaciens subtilisin. Further, they are those residues of the precursor carbonyl hydrolase (for which a tertiary structure has been obtained by x-ray crystallography) which occupy an analogous position to the extent that, although the main chain atoms of the given residue may not satisfy the criteria of equivalence on the basis of occupying a homologous position, the atomic coordinates of at least two of the side chain atoms of the residue lie with 0.13nm of the corresponding side chain atoms of Bacillus amyloliquefaciens subtilisin. The coordinates of the three dimensional structure of Bacillus amyloliquefaciens subtilisin are set forth in EPO
Publication No. 0 251 446 (equivalent to US Patent Application SN 08/212,291, the disclosure of which is incorporated herein by reference) and can be used as outlined above to determine equivalent residues on the level of tertiary structure.
Some of the residues identified for substitution, insertion or deletion are conserved residues whereas others are not. In the case of residues which are not conserved, the replacement of one or more amino acids is limited to substitutions which produce a variant which has an amino acid sequence that does not correspond to one found in nature. In the case of conserved residues, such
replacements should not result in a naturally-occurring sequence. The carbonyl hydrolase variants of the present invention include the mature forms of carbonyl hydrolase variants, as well as the pro- and prepro-forms of such hydrolase variants. The prepro-forms are the preferred construction since this facilitates the expression, secretion and maturation of the carbonyl hydrolase variants.
"Prosequence" refers to a sequence of amino acids bound to the N-terminal portion of the mature form of a carbonyl hydrolase which when removed results in the appearance of the "mature" form of the carbonyl hydrolase. Many proteolytic enzymes are found in nature as translational proenzyme products and, in the absence of post-translational processing, are expressed in this fashion. A
preferred prosequence for producing carbonyl hydrolase variants, specifically subtilisin variants, is the putative prosequence of Bacillus amyloliquefaciens subtilisin, although other subtilisin prosequences may be used. In Examples 1 and 2 the putative
prosequence from the subtilisin from Bacillus lentus (ATCC 21536) was used.
A "signal sequence" or "presequence" refers to any sequence of amino acids bound to the N-terminal portion of a carbonyl hydrolase or to the N-terminal portion of a prohydrolase which may participate in the secretion of the mature or pro forms of the hydrolase. This definition of signal sequence is a functional one, meant to include all those amino acid sequences encoded by the N-terminal portion of the subtilisin gene or other secretable carbonyl hydrolases which participate in the effectuation of the secretion of subtilisin or other carbonyl hydrolases under native conditions. The present invention utilizes such sequences to effect the secretion of the carbonyl hydrolase variants as defined herein. A preferred signal sequence used in the Examples comprises the first seven amino acid residues of the signal sequence from Bacillus subtilis subtilisin fused to the remainder of the signal sequence of the subtilisin from Bacillus lentus (ATCC 21536).
A "prepro" form of a carbonyl hydrolase variant consists of the mature form of the hydrolase having a prosequence operably linked to the amino terminus of the hydrolase and a "pre" or "signal" sequence operably linked to the amino terminus of the prosequence.
"Expression vector" refers to a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of said DNA in a suitable host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites and sequences which control termination of transcription and translation. The vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. In the present specification, "plasmid" and "vector" are sometimes used
interchangeably as the plasmid is the most commonly used form of vector at present. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.
The "host cells" used in the present invention generally are procaryotic or eucaryotic hosts which preferably have been
manipulated by the methods disclosed in US Patent 4,760,025 (RE 34,606) to render them incapable of secreting enzymatically active endoprotease. A preferred host cell for expressing subtilisin is the Bacillus strain BG2036 which is deficient in enzymatically active neutral protease and alkaline protease (subtilisin). The construction of strain BG2036 is described in detail in US Patent 5,264,366. Other host cells for expressing subtilisin include Bacillus subtilis 1168 (also described in US Patent 4,760,025 (RE 34,606) and US Patent 5,264,366, the disclosure of which are incorporated herein by reference), as well as any suitable Bacillus strain such as B. licheniformis, B. lentus , etc.
Host cells are transformed or transfected with vectors constructed using recombinant DNA techniques. Such transformed host cells are capable of either replicating vectors encoding the carbonyl
hydrolase variants or expressing the desired carbonyl hydrolase variant. In the case of vectors which encode the pre- or prepro-form of the carbonyl hydrolase variant, such variants, when
expressed, are typically secreted from the host cell into the host cell medium.
"Operably linked, " when describing the relationship between two DNA regions, simply means that they are functionally related to each other. For example, a presequence is operably linked to a peptide if it functions as a signal sequence, participating in the secretion of the mature form of the protein most probably involving cleavage of the signal sequence. A promoter is operably linked to a coding sequence if it controls the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.
The genes encoding the naturally-occurring precursor carbonyl hydrolase may be obtained in accord with the general methods known to those skilled in the art . The methods generally comprise synthesizing labeled probes having putative sequences encoding regions of the hydrolase of interest, preparing genomic libraries from organisms expressing the hydrolase, and screening the libraries for the gene of interest by hybridization to the probes. Positively hybridizing clones are then mapped and sequenced. The B. lentuε gene used in the Examples was cloned as described in Example 1 of US Patent 5,185,258, the disclosure of which is incorporated herein. The BPN' gene used in Example 5 was cloned as described in Example 1 in RE 34,606, the disclosure of which is incorporated herein.
The cloned carbonyl hydrolase is then used to transform a host cell in order to express the hydrolase. The hydrolase gene is then ligated into a high copy number plasmid. This plasmid replicates in hosts in the sense that it contains the well-known elements
necessary for plasmid replication: a promoter operably linked to the gene in question (which may be supplied as the gene's own homologous promotor if it is recognized, i.e., transcribed, by the host) , a transcription termination and polyadenylation region
(necessary for stability of the mRNA transcribed by the host from the hydrolase gene in certain eucaryotic host cells) which is exogenous or is supplied by the endogenous terminator region of the hydrolase gene and, desirably, a selection gene such as an
antibiotic resistance gene that enables continuous cultural
maintenance of plasmid-infected host cells by growth in antibiotic- containing media. High copy number plasmids also contain an origin of replication for the host, thereby enabling large numbers of plasmids to be generated in the cytoplasm without chromosomal limitations. However, it is within the scope herein to integrate multiple copies of the hydrolase gene into host genome. This is facilitated by procaryotic and eucaryotic organisms which are particularly susceptible to homologous recombination. The genes used in the present examples are a natural B. lentus gene and a natural B. amyloliguefaciens gene. Alternatively, a synthetic gene encoding a naturally-occurring or mutant precursor carbonyl hydrolase (subtilisin) may be produced. In such an approach, the DNA and/or amino acid sequence of the precursor hydrolase
(subtilisin) is determined. Multiple, overlapping synthetic single- stranded DNA fragments are thereafter synthesized, which upon hybridization and ligation produce a synthetic DNA encoding the precursor hydrolase. An example of synthetic gene construction is set forth in Example 3 of US Patent 5,204,015, the disclosure of which is incorporated herein by reference.
Once the naturally-occurring or synthetic precursor carbonyl hydrolase gene has been cloned, a number of modifications are undertaken to enhance the use of the gene beyond synthesis of the naturally-occurring precursor carbonyl hydrolase . Such
modifications include the production of recombinant carbonyl hydrolases as disclosed in US Patent 4,760,025 (RE 34,606) and EPO Publication No. 0 251 446 and the production of carbonyl hydrolase variants described herein.
The following cassette mutagenesis method may be used to facilitate the construction and identification of the carbonyl hydrolase variants of the present invention, although other methods including site-directed mutagenesis may be used. First, the naturally- occurring gene encoding the hydrolase is obtained and seguenced in whole or in part. Then the sequence is scanned for a point at which it is desired to make a mutation (deletion, insertion or
substitution) of one or more amino acids in the encoded enzyme. The sequences flanking this point are evaluated for the presence of restriction sites for replacing a short segment of the gene with an oligonucleotide pool which when expressed will encode various mutants. Such restriction sites are preferably unique sites within the hydrolase gene so as to facilitate the replacement of the gene segment. However, any convenient restriction site which is not overly redundant in the hydrolase gene may be used, provided the gene fragments generated by restriction digestion can be reassembled in proper sequence. If restriction sites are not present at locations within a convenient distance from the selected point (from 10 to 15 nucleotides) , such sites are generated by substituting nucleotides in the gene in such a fashion that neither the reading frame nor the amino acids encoded are changed in the final
construction. Mutation of the gene in order to change its sequence to conform to the desired sequence is accomplished by M13 primer extension in accord with generally known methods. The task of locating suitable flanking regions and evaluating the needed changes to arrive at two convenient restriction site sequences is made routine by the redundancy of the genetic code, a restriction enzyme map of the gene and the large number of different restriction enzymes. Note that if a convenient flanking restriction site is available, the above method need be used only in connection with the flanking region which does not contain a site.
Once the naturally-occurring DNA or synthetic DNA is cloned, the restriction sites flanking the positions to be mutated are digested with the cognate restriction enzymes and a plurality of end termini-complementary oligonucleotide cassettes are ligated into the gene. The mutagenesis is simplified by this method because all of the oligonucleotides can be synthesized so as to have the same
restriction sites, and no synthetic linkers are necessary to create the restriction sites.
As used herein, proteolytic activity is defined as the rate of hydrolysis of peptide bonds per milligram of active enzyme. Many well known procedures exist for measuring proteolytic activity (K. M. Kalisz, "Microbial Proteinases, " Advances in Biochemical
Engineering/Biotechnology, A. Fiechter ed., 1988). In addition to or as an alternative to modified proteolytic activity, the variant enzymes of the present invention may have other modified properties such as Km, kcat, kcat/Km ratio and/or modified substrate specificity and/or modified pH activity profile. These enzymes can be tailored for the particular substrate which is anticipated to be present, for example, in the preparation of peptides or for hydrolytic processes such as laundry uses.
In one aspect of the invention the objective is to secure a variant carbonyl hydrolase having altered proteolytic activity as compared to the precursor carbonyl hydrolase, since increasing such activity (numerically larger) enables the use of the enzyme to more
efficiently act on a target substrate. Also of interest are variant enzymes having altered thermal stability and/or altered substrate specificity as compared to the precursor. Preferably the carbonyl hydrolase to be mutated is a subtilisin. Specific amino acids useful to obtain such results in subtilisin-type carbonyl hydrolases at residues equivalent to +76, +99, +101, +103, +104, +107, +123 +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 or any combination thereof in Bacillus amyloliquefaciens subtilisin are presented in the Examples. In some instances, lower proteolytic activity may be desirable, for example a decrease in proteolytic activity would be useful where the synthetic activity of the carbonyl hydrolases is desired (as for synthesizing peptides). One may wish to decrease this proteolytic activity, which is capable of destroying the product of such synthesis. Conversely, in some instances it may be desirable to increase the proteolytic activity of the variant enzyme versus its precursor. Additionally, increases or decreases (alteration) of the stability of the variant, whether alkaline or thermal stability, may be desirable. Increases or decreases in kcat, Km or kcat/Km are specific to the substrate used to determine these kinetic parameters.
In another aspect of the invention, it has been determined that residues equivalent to +76 in combination with a number of other modifications in subtilisin are important in modulating overall stability and/or proteolytic activity of the enzyme. Thus, as set forth in the Examples, the Asparagine (N) in Bacillus lentus subtilisin at equivalent position +76 can be substituted with
Aspartate (D) in the preferred embodiment in combination with modification of one or more of the following amino acid residues +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274, to produce enhanced stability and/or enhanced activity of the resulting mutant enzyme.
The most preferred embodiments of the invention are set forth in the Examples. These include the following specific combinations of substituted residues: N76D/S99D; N76D/V104I; N76D/S99D/V104I;
N76D/S103A/V104I; N76D/V104I/I107V; N76D/V104Y/I107V and
N76D/S101R/S103A/V104I. Also described in the Examples are all mutant combinations claimed in the present invention. These substitutions are preferably made in Bacillus lentus (recombinant or native-type) subtilisin, although the substitutions may be made in any Bacillus subtilisin. Based on the results obtained with this and other variant subtilisins, it is apparent that residues in carbonyl hydrolases (preferably subtilisin) equivalent to positions +76, +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 in Bacillus amyloliquefaciens are important to the proteolytic activity, performance and/or stability of these enzymes and the cleaning or wash performance of such variant enzymes .
Many of the carbonyl hydrolase variants of the invention, especially subtilisin, are useful in formulating various detergent
compositions. A number of known compounds are suitable surfactants useful in compositions comprising the carbonyl hydrolase mutants of the invention. These include nonionic, anionic, cationic, anionic or zwitterionic detergents, as disclosed in US 4,404,128 to Barry J. Anderson and US 4,261,868 to Jiri Flora, et al. A suitable
detergent formulation is that described in Example 7 of US Patent 5,204,015 (previously incorporated by reference). The art is familiar with the different formulations which can be used as cleaning compositions. In addition to typical cleaning
compositions, it is readily understood that the subtilisin variants of the present invention may be used for any purpose that native or wild-type subtilisins are used. Thus, these variants can be used, for example, in bar or liquid soap applications, dishcare
formulations, contact lens cleaning solutions or products, peptide hydrolysis, waste treatment, textile applications, as fusion- cleavage enzymes in protein production, etc. The variants of the present invention may comprise enhanced performance in a detergent composition (as compared to the precursor) . As used herein, enhanced performance in a detergent is defined as increasing cleaning of certain enzyme sensitive stains such as grass or blood, as determined by usual evaluation after a standard wash cycle.
Subtilisins of the invention can be formulated into known powdered and liquid detergents having pH between 6.5 and 12.0 at levels of about .01 to about 5% (preferably .1% to .5%) by weight. These detergent cleaning compositions can also include other enzymes such as known proteases, amylases, cellulases, lipases or
endoglycosidases, as well as builders and stabilizers. The addition of subtilisins of the invention to conventional cleaning compositions does not create any special use limitation. In other words, any temperature and pH suitable for the detergent is also suitable for the present compositions as long as the pH is within the above range, and the temperature is below the described subtilisin's denaturing temperature. In addition, subtilisins of the invention can be used in a cleaning composition without
detergents, again either alone or in combination with builders and stabilizers.
The following is presented by way of example and is not to be construed as a limitation to the scope of the claims.
Example 1
Construction for the Expression of GG36 Gene in B . subtilis
The cloning and the construction for expression of the subtilisin gene from B . lentus was performed essentially the same as that described in US Patent 5,185,258. The plasmid GGA274 (described in Fig. 4 herein) was further modified in the following manner, as shown in Fig. 5. The PstI site that was introduced during the construction of the GGA274 plasmid was removed by the
oligonucleotide directed mutagenesis described below, with an oligonucleotide having the following sequence: 5'
GAAGCTGCAACTCGTTAAA 3' (Seq. ID No.1). The underlined "A" residue eliminated the recognition sequence of restriction enzyme PstI and changed the corresponding amino acid residue from alanine to threonine at position 274. Threonine at position 274 is the wild-type residue originally found in the cloned B . lentus subtilisin gene sequences. The DNA segment encoding subtilisin was excised from the plasmid GGA274 or its derivatives (GGT274 shown in Fig. 5) by EcoRI and BamHI digest. The DNA fragment was subcloned back into Bacteriophage M13 -based vectors, such as MP19, for mutagenesis.
After mutagenesis, the EcoRI and HindIII digest, followed by cloning, were performed to move the mutated subtilisin gene back into an expression plasmid like GGA274 for the expression and the recovery of mutated subtilisin proteins.
Example 2
Oligonucleotide-Directed Mutagenesis
Oligonucleotide-directed mutagenesis was performed as described in Zoller, M., et al. (1983), Methods Enzymol., 100:468-500. As an example, a synthetic oligonucleotide of the sequence 5' GCTGCTCTAGACAATTCG 3' (Seq. ID No.2) was used to change the amino acid residue at position 76 from asparagine (N) to aspartic acid (D), or N76D. The underlined "G" and "C" residues denote changes from the wild-type gene sequence. The CA keeps the leucine at position +75 and changes the amino acid sequence to introduce an XbaI recognition site of the XbaI restriction enzyme (TCTAGA), while the change at GAC changes asparagine at +76 to aspartate.
For mutagenesis at positions 99, 101, 103 and 104, different oligonucleotides can be used depending on the combination of mutations desired. For example, an oligonucleotide of the sequence 5' GTATTAGGGGCGGACGGTCGAGGCGCCATCAGCTCGATT 3' (Seq. ID No .3 ) was used to simultaneously make the following changes: S99D; S101R; S103A and V104I in a single subtilisin molecule. Similarly,
oligonucleotides of the sequence 5'
TCAGGTTCGGTCTCGAGCGTTGCCCAAGGATTG 3' (Seq. ID No.4) and 5'
CACGTTGCTAGCTTGAGTTTAG 3' (Seq. ID No.5) were utilized to generate I107V and N123S, respectively. Again, the underlined residues denote changes from wild-type sequences which produced desired changes either in amino acid sequences or restriction enzyme recognition sequences.
Example 3
Proteolytic Activity of Subtilisin Variants
Following the methods of Example 2, the variants listed in Table III were made. Proteolytic activity of each of these subtilisin variants is shown in Table III. The kinetic parameters kcat, KM, and kcat/KM were measured for hydrolysis of the synthetic peptide
substrate succinyl-L-Ala-L-Ala-L-Pro-L-Phe-p-nitroanilide using the method described in P. Bonneau, et al. (1991) J. Am. Chem. Soc., Vol. 113, No. 3, p. 1030. Briefly, a small aliquot of subtilisin variant stock solution was added to a 1 cm cuvette containing substrate dissolved in 0.1M Tris-HCL buffer, pH 8.6, and
thermostated at 25°C. The reaction progress was followed
spectrophotometrically by monitoring the absorbance of the reaction product p-nitroaniline at 410 nm. Kinetic parameters were obtained by using a non-linear regression algorithm to fit the reaction velocity and product concentration for. each reaction to the
Michaelis-Menten equation. Table III
Kinetic Parameters kcat , KM and kcat/KM
Measured for Bacillus lentus Subtilisin and Variants
Enzyme ( s-1 ) KM (M) kcat/KM ( s-1M-1 )
B . lentus Subtilisin 170 0.00078 2.18×105
N76D 219 0.0008 2.74×105
N76D/S99D 88 0.00061 1.44×105
N76D/S103A 400 0.0014 2.86×105
N76D/V104I 459 0.0011 4.17×105
N76D/I107V 219 0.0011 1.99×105
N76D/N123S 115 0.0018 6.40×104
N76D/S99D/S101R 146 0.00038 3.84×105
N76D/S99D/S103A 157 0.0012 1.31×105
N76D/S99D/V104I 247 0.00097 2.55×105
N76D/S101R/S103A 405 0.00069 5.90×105
N76D/S101R/V104I 540 0.00049 1.10×106
N76D/S103A/V104I 832 0.0016 5.20×105
N76D/V104I/I107V 497 0.00045 1.10×106
N76D/V104Y/I107V 330 0.00017 1.90×106
N76D/V104I/N123S 251 0.0026 9.65×104
N76D/I107V/N123S 147 0.0035 4.20×104
N76D/S99D/S101R/S103A 242 0.00074 3.27×105
N76D/S99D/S101R/V104I 403 0.00072 5.60×105
N76D/S99D/S103A/V104I 420 0.0016 2.62×105
N76D/S101R/S103A/V104I 731 0.00065 1.12×106
N76D/S103A/V104I/N123S 321 0.0026 1.23×105
N76D/V104I/I107V/N123S 231 0.003 7.70×104
N76D/S99D/S101R/S103A/V104I 624 0.00098 6.37×105
N76D/S99D/S103A/V104I/N123S 194 0.0043 4.51×104
N76D/S99D/S101R/S103A/V104I /N123S 311 0.0023 1.35×105
The results listed in Table III indicate that all of the subtilisin variants tested retain proteolytic activity. Further, detailed analysis of the data reveal that proteolytic activity was
significantly altered for Bacillus lentus subtilisin by the various combinations of substitutions at amino acid residues equivalent to positions 76, 99, 101, 103, 104, 107 and 123 in Bacillus
amyloliquefaciens . Example 4
Thermal Stability of Subtilisin Variants
A comparison of thermal stability observed for Bacillus lentus subtilisin and the variants of the present invention made by the process of Example 2 is shown in Table IV. Purified enzyme, 15 ug/ml in 0.1 M glycine 0.01% Tween-80 pH 10.0, with or without 50 mM CaCl2, was aliquotted into small tubes and incubated at 10°C for 5 minutes, 10°C to 60°C over 1 minute, and 60°C for 20 minutes. Tubes were then placed on ice for 10 minutes. Aliquots from the tubes were assayed for enzyme activity by addition to 1 cm cuvettes containing 1.2 mM of the synthetic peptide substrate succinyl-L-ala-L-Ala-L-Pro-L-Phe-p-nitroanilide dissolved in 0.1 M tris-HCL buffer, pH 8.6, thermostatted at 25°C. The initial linear reaction velocity was followed spectrophotometrically by monitoring the absorbance of the reaction product p-nitroaniline at 410 nm as a function of time. Data are presented as percent activity prior to heating. The results listed in Table IV indicate that a vast majority of variants exhibit thermal stability comparable to Bacillus lentus subtilisin (24 out of 26) in the test condition with 50mM CaCl2 added. In the test condition without 50mM CaCl2 added, a vast majority of variants (19 out of 26) are significantly more stable than Bacillus lentus subtilisin. Further, the variants N76D/S99D, N76D/V104I,
N76D/S99D/V104I, N76D/S103A/V104I, N76D/V104I/I107V,
N76D/V104Y/I107V and N76D/S101R/S103A/V104I are significantly more stable than the single substitution variant N76D in the test condition without 50mM CaCl2 added.
Table IV
Thermal Stability Measured for Bacillus lentus Subtilisin and Variants
At pH 10 , 60 °C , + / - 50mM CaCl2 Added
% Initial Activity Remaining
Enzyme - CaCl2 + CaCl2
B . lentus Subtilisin 2 96
N76D 34 97
N76D/S99D 49 98
N76D/S103A 26 92
N76D/V104I 58 98
N76D/I107V 32 96
N76D/N123S 0 97
N76D/S99D/S101R 30 100
N76D/S99D/S103A 36 100
N76D/S99D/V104I 48 97
N76D/S101R/S103A 26 100
N76D/S101R/V104I 38 100
N76D/S103A/V104I 58 100
N76D/V104I/I107V 60 97
N76D/V104Y/I107V 48 74
N76D/V104I/N123S 0 98
N76D/I107V/N123S 16 100
N76D/S99D/S101R/S103A 38 100
N76D/S99D/S101R/V104I 33 100
N76D/S99D/S103A/V104I 38 98
N76D/S101R/S103A/V104I 40 99
N76D/S103A/V104I/N123S 1 98
N76D/V104I/I107V/N123S 3 99
N76D/S99D/S101R/S103A/V104I 36 99
N76D/S99D/S103A/V104I/N123S 2 95
N76D/S99D/S101R/S103A/V104I/N123S 0 100
Example 5
Oligonucleotide-Directed Mutagenesis with Single-Stranded DNA Template Generated from Phagemid A. Construction of B . lentus Variants
The mutagenesis protocol was essentially the same as described above in Example 2. The single-stranded DNA template was generated by phagemid method. To construct the phagemid vector for generating the single-stranded DNA template we first constructed the vector pBCDAICAT. The flow chart of vector construction is outlined in Figure 8. First, the ClaI to ClaI fragment encoding the CAT gene from pC194 plasmid (Horinouchi, S. and Weisblum, B., J. Bacteriol., 150:8-15, 1982) was cloned into the Accl site of polylinker region of pUC19 (New England BioLabs, Beverly, MA) to make plasmid pUCCHL and the EcoRI-Dral 0.6 KB fragment from the 5' end of the GG36DAI encoding DNA was cloned into the EcoRI and EcoRV sites of pBSKS plasmid (Stratagene, Inc., San Diego, CA) to make pBC2SK5. The single EcoRI site of the plasmid pBC2SK5 was eliminated by EcoRI digestion, followed by filling in catalyzed-by-T4 DNA polymerase, and religation to generate the plasmid pBC2SK-5R which does not have the EcoRI site. The EcoRI-Dral fragment which was cloned into pBCSK-5R was isolated as a PstI-HindIII fragment and cloned into the PstI-HindIII site of the pUCCHL (part of the polylinker of pUC19) to generate plasmid pUCCHL5R. The encoding sequence of GG36DAI gene was excised as an EcoRI-BamHI fragment and cloned into the EcoRI-BamHI sites of pUCCHL5R to make pUCCAT. The large EcoRI-HindIII fragment of pUCCAT was then cloned into the EcoRI and HindIII sites of BS2KS+ to generate the plasmid pBCDAICAT.
To generate single-stranded DNA, E. coli-containing pBCDAICAT were infected with phage R408 (obtained from Stratagene, San Diego, CA) following the protocol described in Russel, M., Kidd, S. and Kelley, M.R., GENE 45:333-338, 1986. Once the single-stranded DNA template was available, standard mutagenesis methods as described above in Example 2 were carried out. The construction of certain mutants is detailed below for illustrative purposes.
For the construction of B. lentus (GG36) N76D/S103A/V104I/L217H, an EcoRI-BamHI DNA fragment encoding GG36 N76D/S103A/V104I was used in the construction of pUCCAT (see Fig. 8) to generate the plasmid pBCDAICAT. After the single-stranded DNA template was made following the protocol described above, a mutagenesis primer with the following sequence
* *** ** x claI
5' TAT GCC AGC CAC AAC GGT ACT TCG ATG GCT 3' (Seq. ID No.13) was used to make the L217H. As before, the underlined residues denote the nucleotide changes that were made and the x ClaI indicates that the existing ClaI site was eliminated after the mutagenesis. The mutagenesis protocol was as described in Example 2. After the mutagenesis, plasmid DNA was first screened for the elimination of the ClaI site and those clones missing the ClaI site were subjected to DNA sequence analysis to verify the DNA sequence which made the L to H change at the 217th amino acid residue.
B. Construction of BPN' Variants and their Expression in B.
subtilis
The construction of B . amyloliquefaciens (BPN')
N76D/Q103A/Y104I/Y217L was done in a similar fashion except in two consecutive steps. N76D was first introduced into BPN' Y217L to make BPN' N76D/Y217L and a second mutagenesis was done to convert BPN' N76D/Y217L to BPN' N76D/Q103A/Y104I/Y217L. To generate the single-stranded DNA template for the first mutagenesis, an EcoRI-BamHI fragment encoding BPN' Y217L subtilisin (derived from the Y217L plasmid described in Wells, J., et al., PNAS, 84, 5167, 1087) was used to construct a plasmid pUCCATFNA (see Fig. 9). The pUCCATFNA plasmid containing BPN' Y217L was used to construct the pBCFNACAT plasmid (Fig. 9). Single-stranded DNA was generated as described above. To generate BPN' N76D/Y217L, an oligonucleotide primer with the sequence
* *** ** x XbaI
5' C ACA GTT GCG GCT CTA GAT AAC TCA ATC GGT G 3' (Seq. ID No.14)
was used to generate the change N76D. Single-stranded DNA was then prepared from the pBCFNACAT plasmid containing the BPN' N76D/Y217L (the pBCFNACAT plasmid after N76D mutagenesis) and mutagenized with another oligonucleotide with the sequence
* *** ** x PvuII
5' GCT GAC GGT TCC GGC GCT ATT AGT TGG ATC ATT 3' ( Seq. ID No.15)
to obtain BPN' N76D/Q103A/Y104I/Y217L. All steps involved in the cloning, the single-stranded DNA preparation, the mutagenesis, and the screening for mutants were carried out as described above. Expression of the BPN' gene and its variants were achieved by integrating plasmid DNA (pBCFNACAT containing the different
variants' BPN' gene) directly into a protease-deficient strain of Bacillus subtilis as described in RE 34,606.
Numerous variants were made as per the teachings of Examples 2 and 5. Kinetics data and stability data were generated for such variants. The kinetics data were generated using the methods described in Example 3 and are provided in Table V. The stability data were generated as detailed herein. Results are shown in Table VI.
Thermal Stability Assay Procedure
Purified enzyme was buffer-exchanged into 0.1 M glycine pH 10.0, 0.01% Tween-80 by applying the enzyme to a column consisting of Sephadex G-25 equilibrated with this buffer and eluting the enzyme from the column using the same buffer.
To a tube containing 0.1 M glycine, 0.01% Tween-80 pH 10.0
thermostatted at 60°C, the buffer-exchanged enzyme was added to give a final enzyme concentration of 15 ug/ml.
Aliquots were removed from the 60°C incubation at various times and immediately assayed for enzyme activity by addition to a 1 cm cuvette containing 1.2 mM of the synthetic peptide substrate succinyl-L-Ala-L-Ala-L-Pro-L-Phe-p-nitroanilide dissolved in 0.1 M tris-HCL buffer, pH 8.6, thermostatted at 25°C. The initial linear reaction velocity was followed spectrophotometrically by monitoring the absorbance of the reaction product p-nitroaniline at 410 nm as a function of time.
Half-life, which is the length of time required for 50% enzyme inactivation, was determined from the first-order plot of reaction velocity as a function of the time of incubation at 60°C.
The data are presented in Table VI as percent of the half-life determined for Bacillus lentus subtilisin (GG36) under identical conditions. Table V
Enzyme kcat KM kcat/KM
(s-1) (mM) (s-1M-1)
B. lentus subtilisin 170 0.78 2.20E+05
N76D/S103G/V104I* 380 1.4 2.70E+05
N76D/S103A/V104F 730 0.33 2.20E+06
N76D/S103A/V104N 790 2.8 2.80E+05
N76D/S103A/V104S 170 0.83 2.00E+05
N76D/S103A/V104T 370 1.9 2.00E+05
N76D/S103A/V104W 880 0.31 2.80E+06
N76D/S103A/V104Y 690 0.5 1.40E+06
K27R/N76D/V104Y/N123S 500 1.2 4.20E+05
N76D/S101G/S103A/V104I* 620 1.3 4.80E+05
N76D/S103A/V104I/S105A* 550 1.3 4.20E+05
N76D/S103A/V104I/S105D* 440 1.7 2.60E+05
N76D/S103A/V104T/I107A* 120 5.7 2.10E+04
N76D/S103A/V104T/I107L* 310 3.2 9.70E+04
N76D/S103A/V104I/L126A 90 2.2 4.10E+04
N76D/S103A/V104I/L126F 180 1.9 9.50E+04
N76D/S103A/V104I/L126I 100 2.4 4.20E+04
N76D/S103A/V104I/L126V 64 3.2 2.00E+04
N76D/S103A/V104I/S128G* 560 1.7 3.30E+05
N76D/S103A/V104I/S128L* 430 3.8 1.10E+05
N76D/S103A/V104I/L135A 140 0.76 1.80E+05
N76D/S103A/V104I/L135F 390 0.69 5.70E+05
N76D/S103A/V104I/L135I 110 0.73 1.50E+05
N76D/S103A/V104I/L135V 140 0.86 1.60E+05
N76D/S103A/V104I/S156E* 170 2.6 6.50E+04
N76D/S103A/V104I/S166D* 160 3.5 4.60E+04
N76D/S103A/V104I/D197E 510 1.4 3.60E+05
N76D/S103A/V104I/N204A* 530 1.1 4.80E+05
N76D/S103A/V104I/N204G* 580 1.4 4.10E+05
N76D/S103A/V104I/N204C* 370 1.3 2.90E+05
N76/S103A/V104I/P210I* 500 1.2 4.20E+05
N76D/S103A/V104I/L217H* 80 0.63 1.30E+05
N76D/S103A/V104I/M222A 70 3.1 2.30E+04
N76D/S103A/V104I/M222S 80 3.1 2.60E+04
N76D/S103A/V104I/T260P 660 1.5 4.40E+05
N76D/S103A/V104I/S265N 590 1.3 4.50E+05
K27R/N76D/V104Y/I107V/N123S 220 1.4 1.60E+05
K27R/N76D/V104Y/N123S/D197E 430 1.1 3.90E+05
K27R/N76D/V104Y/N123S/N204C 400 1.1 3.60E+05
K27R/N76D/V104Y/N123S/Q206L 440 1.2 3.70E+05
K27R/N76D/V104Y/N123S/S216V 440 1.2 3.70E+05
K27R/N76D/V104Y/N123S/N218S 760 0.98 7.80E+05
K27R/N76D/V104Y/N123S/T260P 410 1.2 3.40E+05
K27R/N76D/V104Y/N123S/T274A 390 1 3.90E+05
N76D/S103A/V104I/L126F/S265N 170 2.1 8.10E+04
N76D/S103A/V104I/S156E/S166D* 40 6.3 6.40E+03
K27R/N76D/V104Y/N123S/G195E/G197E 410 0.98 4.20E+05
K27R/N76D/V104Y/N123S/G195E/N218S 540 0.66 8.20E+05
K27R/N76D/V104Y/N123S/D197E/N218S 770 0.79 9.80E+05
K27R/N76D/V104Y/N123S/N204C/N218S 610 0.99 6.20E+05
K27R/N76D/V104Y/N123S/Q206L/N218S 580 0.78 7.40E+05
K27R/N76D/V104Y/N123S/N218S/T260P 660 1 6.60E+05
K27R/N76D/V104Y/N123S/N218S/T274A 590 0.89 6.60E+05
K27R/N76D/V104Y/Q109S/N123S/N218S/T2774A 520 1 5.20E+05 K27R/N76D/V104Y/N123S/G195E/D197E/N218S 460 0.65 7.10E+05
B. amyloliquefaciens subtilisin (BPN') 50 0.14 3.60E+05 BPN'-N76D/Y217L* 380 0.46 8.30E+05
* These mutants made as per Example 5, all others made as per Example 2
Table VI
Enzyme Thermal Stability
(% half-life of native enzyme)
B. lentus subtilisin 100
N76D 590
N76D/S99D 840
N76D/S103A 390
N76D/V104I 660
N76D/I107V 710
N76D/N123S 70
N76D/S99D/S101R 610
N76D/S99D/S103A 590
N76D/S99D/V104I 910
N76D/S101R/S103A 930
N76D/S101R/V104I 500
N76D/S103A/V104I 460
N76D/S103G/V104I* 370
N76D/S103A/V104F 480
N76D/S103A/V104N 230
N76D/S103A/V104S 230
N76D/S103A/V104T 370
N76D/S103A/V104W 280
N76D/S103A/V104Y 400
N76D/V104I/I107V 940
N76D/V104Y/I107V 820
N76D/V104I/N123S 80
N76D/I107V/N123S 150
K27R/N76D/V104Y/N123S 100
N76D/S99D/S101R/S103A 570
N76D/S99D/S101R/V104I 1000
N76D/S99D/S103A/V104I 680
N76D/S101G/S103A/V104I* 390
N76D/S101R/S103A/V104I 470
N76D/S103A/V104I/S105A* 360
N76D/S103A/V104I/S105D* 370
N76D/S103A/V104T/I107A* 270
N76D/S103A/V104T/I107L* 230
N76D/S103A/V104I/N123S 110
N76D/V104I/I107V/N123S 220
N76D/S103A/V104I/L126A 270
N76D/S103A/V104I/L126F 950
N76D/S103A/V104I/L126I 410 N76D/S103A/V104I/L126V 320
N76D/S103A/V104I/S128G* 640
N76D/S103A/V104I/S128L* 760
N76D/S103A/V104I/L135A 230
N76D/S103A/V104I/L135F 200
N76D/S103A/V104I/L135I 510
N76D/S103A/V104I/L135V 500
N76D/S103A/V104I/S156E* 120
N76D/S103A/V104I/S166D* 590
N76D/S103A/V104I/D197E 460
N76D/S103A/V104I/N204A* 230
N76D/S103A/V104I/N204G* 240
N76D/S103A/V104I/N204C* 500
N76D/S103A/V104I/P210I* 1370
N76D/S103A/V104I/L217H* 60
N76D/S103A/V104I/M222A 520
N76D/S103A/V104I/M222S 490
N76D/S103A/V104I/T260P 490
N76D/S103A/V104I/S265N 360
K27R/N76D/V104Y/I107V/N123S 210
K27R/N76D/V104Y/N123S/D197E 120
K27R/N76D/V104Y/N123S/N204C 110
K27R/N76D/V104Y/N123S/Q206L 380
K27R/N76D/V104Y/N123S/S216V 140
K27R/N76D/V104Y/N123S/N218S 270
K27R/N76D/V104Y/N123S/T260P 40
K27R/N76D/V104Y/N123S/T274A 60
N76D/S99D/S101R/S103A/V104I 590
N76D/S99D/S103A/V104I/N123S 110
N76D/S103A/V104I/L126F/S265N 810
N76D/S103A/V104I/S156E/S166D* 220
K27R/N76D/V104Y/N123S/G195E/G197E 90
K27R/N76D/V104Y/N123S/G195E/N218S 250
K27R/N76D/V104Y/N123S/D197E/N218S 270
K27R/N76D/V104Y/N123S/N204C/N218S 460
K27R/N76D/V104Y/N123S/Q206L/N218S 1400
K27R/N76D/V104Y/N123S/N218S/T260P 310
K27R/N76D/V104Y/N123S/N218S/T274A 180
N76D/S99D/S101R/S103A/V104I/N123S 90
K27R/N76D/V104Y/Q109S/N123S/N218S/T274A 230
K27R/N76D/V104Y/N123S/G195E/D197E/N218S 240
B. amyloliquefaciens subtilisin (BPN' 100
BPN'-N76D/Y217L* 420
These mutants made as per Example 5, all others made as per Example 2 Example 6
Wash Performance Test
The wash performance of the variants described in the previous examples was evaluated by measuring the removal of stain from EMPA 116 (blood/milk/carbon black on cotton) cloth swatches (Testfabrics, Inc., Middlesex, NJ 07030).
Six EMPA 116 swatches, cut to 3 X 4-1/2 inches with pinked edges, were placed in each pot of a Model 7243S Terg-O-Tometer (United States Testing Co., Inc., Hoboken, NJ) containing 1000 ml of water, 15 gpg hardness (Ca++ :Mg++::3:1::w:w), 7 g of detergent, and enzyme as appropriate. The detergent base was WFK1 detergent from wfk - Testgewebe GmbH, Adlerstrasse 42, Postfach 13 07 62, D-47759
Krefeld, Germany:
Figure imgf000035_0001
To this base detergent, the following additions were made:
Figure imgf000035_0002
Sodium perborate monohydrate was obtained from Degussa Corporation, Ridgefield-Park, NJ 07660. Sokalan CP5 was obtained from BASF Corporation, Parsippany, NJ 07054. Mykon ATC Green (TAED,
tetraacetylethylenediamine) was obtained from Warwick International, Limited, Mostyn, Holywell, Clwyd CH8 9HE, England. Tinopal AMS GX was obtained from Ciba-Geigy Corporation, Greensboro, NC 27419.
Six EMPA 116 swatches were washed in detergent with enzyme for 30 minutes at 60°C and were subsequently rinsed twice for 5 minutes each time in 1000 ml water. Enzymes were added at final
concentrations of 0.05 to 1 ppm for standard curves, and 0.25 ppm for routine analyses. Swatches were dried and pressed, and the reflectance from the swatches was measured using the L value on the L*a*b* scale of a Minolta Chroma Meter, Model CR-200 (Minolta
Corporation, Ramsey, NJ 07446). Performance is reported as a percentage of the performance of B. lentus (GG36) protease and was calculated by dividing the amount of B. lentus (GG36) protease by the amount of variant protease that was needed to provide the same stain removal performance X 100. The data are shown in Table VII.
Table VII
Enzyme Wash Performance
B. lentus subtilisin 100
N76D 310
N76D/S103A 230
N76D/V104I 130
N76D/I107V 160
N76D/S99D/S101R 370
N76D/S99D/S103A 290
N76D/S101R/S103A 130
N76D/S101R/V104I 300
N76D/S103A/V104I 320
N76D/S103G/V104I 160
N76D/S103A/V104F 210
N76D/S103A/V104N 110
N76D/S103A/V104T 170
N76D/V104I/I107V 210
N76D/S99D/S101R/S103A 220
N76D/S99D/S101R/V104I 140
N76D/S101G/S103A/V104I 170
N76D/S101R/S103A/V104I 150
N76D/S103A/V104I/S105A 170
N76D/S103A/V104T/I107A 120
N76D/S103A/V104T/I107L 110
N76D/S103A/V104I/L126F 110
N76D/S103A/V104I/S128G 280
N76D/S103A/V104I/L135I 160
N76D/S103A/V104I/L135V 160
N76D/S103A/V104I/D197E 170
N76D/S103A/V104I/N204A 160
N76D/S103A/V104I/N204G 150
N76D/S103A/V104I/P210I 470
N76D/S103A/V104I/M222A 100
N76D/S103A/V104I/T260P 280
N76D/S103A/V104I/S265N 190
Example 7
Protease Stability in a Liquid Detergent Formulation A comparison of protease stability toward inactivation in a liquid detergent formulation was made for Bacillus lentus subtilisin and it's variant enzyme N76D/S103A/V104I according to the procedure outlined herein. The detergent formulation used for the study was a commercially purchased bottle of Tide Ultra liquid lanudry detergent made in the USA by Procter & Gamble Company. Heat treatment of the detergent formulation was necessary to inactivate in-situ protease. This was accomplished by incubating the detergent at 96°C for a period of 4.5 hours. Concentrated preparations of the B . lentus subtilisin and N76D/S103A/V104I variant, in the range of 20
grams/liter enzyme, were then added to the heat-treated Tide Ultra at room-temperature to a final concentratrion of 0.3 grams/liter enzyme in the detergent formulation. The heat-treated detergent with protease added was then incubated in a water bath thermostatted at 50°C. Aliquots were removed from the incubation tubes at 0, 24, 46, 76, and 112 hour time intervals and assayed for enzyme activity by addition to a 1 cm cuvette containing 1.2 mM of the synthetic peptide substrate suc-Ala-Ala-Pro-phe-p-nitroanilide dissolved in 0.1M tris-HCL buffer, pH 8.6, and thermostatted at 25°C. The initial linear reaction velocity was followed spectrophotometrically by monitoring the absorbance of the reaction product p-nitroaniline at 410nm as a function of time. As shown in Fig. 10, the
N76D/S103A/V104I variant was observed to have significantly greater stability towards inactivation than the native B. lentus enzyme. Estimated half-lives for inactivation in the Tide Ultra detergent formulation for the two enzymes, under the specified test
conditions, are 45 hours for B. lentus subtilisin and 125 hours for the N76D/S103A/V104I variant.
Throughout this application reference is made to various amino acids by way of common one- and three-letter codes. Such codes are identified in Dale, J.W. (1989), Molecular Genetics of Bacteria, John Wiley & Sons, Ltd., Appendix B.
Although the preferred embodiments of the invention have been described above, it will be obvious to those skilled in the art to which the invention pertains, that, after understanding the
invention as a whole, various changes and equivalent modifications may be made without departing from the scope of the invention as defined by the appended claims. SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Graycar, Thomas P
Bott, Richard R
Wilson, Lori J
(ii) TITLE OF INVENTION: Subtilisin Variants
(iii) NUMBER OF SEQUENCES: 15
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genencor International, Inc
(B) STREET: 180 Kimball Way
(C) CITY: So. San Francisco
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 94080
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version # 1 . 25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:- 13-OCT-1994
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Horn, Margaret A.
(B) REGISTRATION NUMBER: 33,401
(C) REFERENCE/DOCKET NUMBER: GC235-2
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (415) 742-7536
(B) TELEFAX: (415) 742-7217
(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
GAAGCTGCAA CTCGTTAAA 19
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
GCTGCTCTAG ACAATTCG 18 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
GTATTAGGGG CGGACGGTCG AGGCGCCATC AGCTCGATT 39
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
TCAGGTTCGG TCTCGAGCGT TGCCCAAGGA TTG 33
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
CACGTTGCTA GCTTGAGTTT AG 22
(2) INFORMATION FOR SEQ ID NO : 6 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1497 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
GGTCTACTAA AATATTATTC CATACTATAC AATTAATACA CAGAATAATC TGTCTATTGG 60
TTATTCTGCA AATGAAAAAA AGGAGAGGAT AAAGAGTGAG AGGCAAAAAA GTATGGATCA 120
GTTTGCTGTT TGCTTTAGCG TTAATCTTTA CGATGGCGTT CGGCAGCACA TCCTCTGCCC 180
AGGCGGCAGG GAAATCAAAC GGGGAAAAGA AATATATTGT CGGGTTTAAA CAGACAATGA 240
GCACGATGAG CGCCGCTAAG AAGAAAGATG TCATTTCTGA AAAAGGCGGG AAAGTGCAAA 300
AGCAATTCAA ATATGTAGAC GCAGCTTCAG TCACATTAAA CGAAAAAGCT GTAAAAGAAT 360 TGAAAAAAGA CCCGAGCGTC GCTTACGTTG AAGAAGATCA CGTAGCACAT GCGTACGCGC 420
AGTCCGTGCC TTACGGCGTA TCACAAATTA AAGCCCCTGC TCTGCACTCT CAAGGCTACA 480
CTGGATCAAA TGTTAAAGTA GCGGTTATCG ACAGCGGTAT CGATTCTTCT CATCCTGATT 540
TAAAGGTAGC AAGCGGAGCC AGCATGGTTC CTTCTGAAAC AAATCCTTTC CAAGACAACA 600
ACTCTCACGG AACTCACGTT GCCGGCACAG TTGCGGCTCT TAATAACTCA ATCGGTGTAT 660
TAGGCGTTGC GCCAAGCGCA TCACTTTACG CTGTAAAAGT TCTCGGTGCT GACGGTTCCG 720
GCCAATACAG CTGGATCATT AACGGAATCG AGTGGGCGAT CGCAAACAAT ATGGACGTTA 780
TTAACATGAG CCTCGGCGGA CCTTCTGGTT CTGCTGCTTT AAAAGCGGCA GTTGATAAAG 840
CCGTTGCATC CGGCGTCGTA GTCGTTGCGG CAGCCGGTAA CGAAGGCACT TCCGGCAGCT 900
CAAGCACAGT GGGCTACCCT GGTAAATACC CTTCTGTCAT TGCAGTAGGC GCTGTTGACA 960
GCAGCAACCA AAGAGCATCT TTCTCAAGCG TAGGACCTGA GCTTGATGTC ATGGCACCTG 1020
GCGTATCTAT CCAAAGCACG CTTCCTGGAA ACAAATACGG GGCGTACAAC GGTACGTCAA 1080
TGGCATCTCC GCACGTTGCC GGAGCGGCTG CTTTGATTCT TTCTAAGCAC CCGAACTGGA 1140
CAAACACTCA AGTCCGCAGC AGTTTAGAAA ACACCACTAC AAAACTTGGT GATTCTTTGT 1200
ACTATGGAAA AGGGCTGATC AACGTACAAG CGGCAGCTCA GTAAAACATA AAAAACCGGC 1260
CTTGGCCCCG CCGGTTTTTT ATTATTTTTC TTCCTCCGCA TGTTCAATCC GCTCCATAAT 1320
CGACGGATGG CTCCCTCTGA AAATTTTAAC GAGAAACGGC GGGTTGACCC GGCTCAGTCC 1380
CGTAACGGCC AACTCCTGAA ACGTCTCAAT CGCCGCTTCC CGGTTTCCGG TCAGCTCAAT 1440
GCCATAACGG TCGGCGGCGT TTTCCTGATA CCGGGAGACG GCATTCGTAA TCGGATC 1497
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 275 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Ala Gln Ser Val Pro Tyr Gly Val Ser Gln Ile Lys Ala Pro Ala Leu
1 5 10 15
His Ser Gln Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val Ile Asp
20 25 30
Ser Gly Ile Asp Ser Ser His Pro Asp Leu Lys Val Ala Gly Gly Ala
35 40 45
Ser Met Val Pro Ser Glu Thr Asn Pro Phe Gln Asp Asn Asn Ser His 50 55 60
Gly Thr His Val Ala Gly Thr Val Ala Ala Leu Asn Asn Ser Ile Gly
65 70 75 80
Val Leu Gly Val Ala Pro Ser Ala Ser Leu Tyr Ala Val Lys Val Leu
85 90 95
Gly Ala Asp Gly Ser Gly Gln Tyr Ser Trp Ile Ile Asn Gly Ile Glu
100 105 110 Trp Ala Ile Ala Asn Asn Met Asp Val Ile Asn Met Ser Leu Gly Gly 115 120 125
Pro Ser Gly Ser Ala Ala Leu Lys Ala Ala Val Asp Lys Ala Val Ala 130 135 140
Ser Gly Val Val Val Val Ala Ala Ala Gly Asn Glu Gly Thr Ser Gly 145 150 155 160
Ser Ser Ser Thr Val Gly Tyr Pro Gly Lys Tyr Pro Ser Val Ile Ala
165 170 175
Val Gly Ala Val Asp Ser Ser Asn Gln Arg Ala Ser Phe Ser Ser Val
180 185 190
Gly Pro Glu Leu Asp Val Met Ala Pro Gly Val Ser Ile Gln Ser Thr
195 200 205
Leu Pro Gly Asn Lys Tyr Gly Ala Tyr Asn Gly Thr Ser Met Ala Ser 210 215 220
Pro His Val Ala Gly Ala Ala Ala Leu Ile Leu Ser Lys His Pro Asn 225 230 235 240
Trp Thr Asn Thr Gln Val Arg Ser Ser Leu Glu Asn Thr Thr Thr Lys
245 250 255
Leu Gly Asp Ser Phe Tyr Tyr Gly Lys Gly Leu Ile Asn Val Gln Ala
260 265 270
Ala Ala Gln
275
( 2 ) INFORMATION FOR SEQ ID NO : 8 :
( i ) SEQUENCE CHARACTERISTICS :
(A) LENGTH : 275 amino acids
(B ) TYPE : amino acid
(C) STRANDEDNESS : single
(D) TOPOLOGY : linear
( ii ) MOLECULE TYPE : protein
(xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 8 :
Ala Gln Ser Val Pro Tyr Gly Ile Ser Gln Ile Lys Ala Pro Ala Leu 1 5 10 15
His Ser Gln Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val Ile Asp
20 25 30
Ser Gly Ile Asp Ser Ser His Pro Asp Leu Asn Val Arg Gly Gly Ala
35 40 45
Ser Phe Val Pro Ser Glu Thr Asn Pro Tyr Gln Asp Gly Ser Ser His 50 55 60
Gly Thr His Val Ala Gly Thr Ile Ala Ala Leu Asn Asn Ser Ile Gly 65 70 75 80
Val Leu Gly Val Ser Pro Ser Ala Ser Leu Tyr Ala Val Lys Val Leu
85 90 95
Asp Ser Thr Gly Ser Gly Gln Tyr Ser Trp Ile Ile Asn Gly Ile Glu
100 105 110
Trp Ala Ile Ser Asn Asn Met Asp Val Ile Asn Met Ser Leu Gly Gly
115 120 125
Pro Thr Gly Ser Thr Ala Leu Lys Thr Val Val Asp Lys Ala Val Ser 130 135 140 Ser Gly Ile Val Val Ala Ala Ala Ala Gly Asn Glu Gly Ser Ser Gly 145 150 155 160
Ser Thr Ser Thr Val Gly Tyr Pro Ala Lys Tyr Pro Ser Thr Ile Ala
165 170 175
Val Gly Ala Val Asn Ser Ser Asn Gln Arg Ala Ser Phe Ser Ser Ala
180 185 190
Gly Ser Glu Leu Asp Val Met Ala Pro Gly Val Ser Ile Gln Ser Thr
195 200 205
Leu Pro Gly Gly Thr Tyr Gly Ala Tyr Asn Gly Thr Ser Met Ala Thr 210 215 220
Pro His Val Ala Gly Ala Ala Ala Leu Ile Leu Ser Lys His Pro Thr 225 230 235 240
Trp Thr Asn Ala Gln Val Arg Asp Arg Leu Glu Ser Thr Ala Thr Tyr
245 250 255
Leu Gly Asn Ser Phe Tyr Tyr Gly Lys Gly Leu Ile Asn Val Gln Ala
260 265 270
Ala Ala Gln
275
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 274 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Ala Gln Thr Val Pro Tyr Gly Ile Pro Leu Ile Lys Ala Asp Lys Val 1 5 10 15 Gln Ala Gln Gly Phe Lys Gly Ala Asn Val Lys Val Ala Val Leu Asp
20 25 30
Thr Gly Ile Gln Ala Ser His Pro Asp Leu Asn Val Val Gly Gly Ala
35 40 45
Ser Phe Val Ala Gly Glu Ala Tyr Asn Thr Asp Gly Asn Gly His Gly 50 55 60
Thr His Val Ala Gly Thr Val Ala Ala Leu Asp Asn Thr Thr Gly Val 65 70 75 80
Leu Gly Val Ala Pro Ser Val Ser Leu Tyr Ala Val Lys Val Leu Asn
85 90 95
Ser Ser Gly Ser Gly Ser Tyr Ser Gly Ile Val Ser Gly Ile Glu Trp
100 105 110
Ala Thr Thr Asn Gly Met Asp Val Ile Asn Met Ser Leu Gly Gly Ala
115 120 125
Ser Gly Ser Thr Ala Met Lys Gln Ala Val Asp Asn Ala Tyr Ala Arg 130 135 140
Gly Val Val Val Val Ala Ala Ala Gly Asn Ser Gly Asn Ser Gly Ser 145 150 155 160
Thr Asn Thr Ile Gly Tyr Pro Ala Lys Tyr Asp Ser Val Ile Ala Val
165 170 175 Gly Ala Val Asp Ser Asn Ser Asn Arg Ala Ser Phe Ser Ser Val Gly 180 185 190
Ala Glu Leu Glu Val Met Ala Pro Gly Ala Gly Val Tyr Ser Thr Tyr
195 200 205
Pro Thr Asn Thr Tyr Ala Thr Leu Asn Gly Thr Ser Met Ala Ser Pro 210 215 220
His Val Ala Gly Ala Ala Ala Leu Ile Leu Ser Lys His Pro Asn Leu 225 230 235 240
Ser Ala Ser Gln Val Arg Asn Arg Leu Ser Ser Thr Ala Thr Tyr Leu
245 250 255
Gly Ser Ser Phe Tyr Tyr Gly Lys Gly Leu Ile Asn Val Glu Ala Ala
260 265 270
Ala Gln
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 269 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
Ala Gln Ser Val Pro Trp Gly Ile Ser Arg Val Gln Ala Pro Ala Ala 1 5 10 15
His Asn Arg Gly Leu Thr Gly Ser Gly Val Lys Val Ala Val Leu Asp
20 25 30
Thr Gly Ile Ser Thr His Pro Asp Leu Asn Ile Arg Gly Gly Ala Ser
35 40 45
Phe Val Pro Gly Glu Pro Ser Thr Gln Asp Gly Asn Gly His Gly Thr 50 55 60
His Val Ala Gly Thr Ile Ala Ala Leu Asn Asn Ser Ile Gly Val Leu
65 70 75 80
Gly Val Ala Pro Ser Ala Glu Leu Tyr Ala Val Lys Val Leu Gly Ala
85 90 95
Ser Gly Ser Gly Ser Val Ser Ser Ile Ala Gln Gly Leu Glu Trp Ala
100 105 110
Gly Asn Asn Gly Met His Val Ala Asn Leu Ser Leu Gly Ser Pro Ser
115 120 125
Pro Ser Ala Thr Leu Glu Gln Ala Val Asn Ser Ala Thr Ser Arg Gly 130 135 140
Val Leu Val Val Ala Ala Ser Gly Asn Ser Gly Ala Gly Ser Ile Ser 145 150 155 160
Tyr Pro Ala Arg Tyr Ala Asn Ala Met Ala Val Gly Ala Thr Asp Gln
165 170 175
Asn Asn Asn Arg Ala Ser Phe Ser Gln Tyr Gly Ala Gly Leu Asp Ile
180 185 190
Val Ala Pro Gly Val Asn Val Gln Ser Thr Tyr Pro Gly Ser Thr Tyr
195 200 205 Ala Ser Leu Asn Gly Thr Ser Met Ala Thr Pro His Val Ala Gly Ala 210 215 220
Ala Ala Leu Val Lys Gln Lys Asn Pro Ser Trp Ser Asn Val Gln Ile 225 230 235 240
Arg Asn His Leu Lys Asn Thr Ala Thr Ser Leu Gly Ser Thr Asn Leu
245 250 255
Tyr Gly Ser Gly Leu Val Asn Ala Glu Ala Ala Thr Arg
260 265
(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1140 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
ATGAAGAAAC CGTTGGGGAA AATTGTCGCA AGCACCGCAC TACTCATTTC TGTTGCTTTT 60
AGTTCATCGA TCGCATCGGC TGCTGAAGAA GCAAAAGAAA AATATTTAAT TGGCTTTAAT 120
GAGCAGGAAG CTGTCAGTGA GTTTGTAGAA CAAGTAGAGG CAAATGACGA GGTCGCCATT 180
CTCTCTGAGG AAGAGGAAGT CGAAATTGAA TTGCTTCATG AATTTGAAAC GATTCCTGTT 240
TTATCCGTTG AGTTAAGCCC AGAAGATGTG GACGCGCTTG AACTCGATCC AGCGATTTCT 300
TATATTGAAG AGGATGCAGA AGTAACGACA ATGGCGCAAT CAGTGCCATG GGGAATTAGC 360
CGTGTGCAAG CCCCAGCTGC CCATAACCGT GGATTGACAG GTTCTGGTGT AAAAGTTGCT 420
GTCCTCGATA CAGGTATTTC CACTCATCCA GACTTAAATA TTCGTGGTGG CGCTAGCTTT 480
GTACCAGGGG AACCATCCAC TCAAGATGGG AATGGGCATG GCACGCATGT GGCCGGGACG 540
ATTGCTGCTT TAAACAATTC GATTGGCGTT CTTGGCGTAG CGCCGAGCGC GGAACTATAC 600
GCTGTTAAAG TATTAGGGGC GAGCGGTTCA GGTTCGGTCA GCTCGATTGC CCAAGGATTG 660
GAATGGGCAG GGAACAATGG CATGCACGTT GCTAATTTGA GTTTAGGAAG CCCTTCGCCA 720
AGTGCCACAC TTGAGCAAGC TGTTAATAGC GCGACTTCTA GAGGCGTTCT TGTTGTAGCG 780
GCATCTGGGA ATTCAGGTGC AGGCTCAATC AGCTATCCGG CCCGTTATGC GAACGCAATG 840
GCAGTCGGAG CTACTGACCA AAACAACAAC CGCGCCAGCT TTTCACAGTA TGGCGCAGGG 900
CTTGACATTG TCGCACCAGG TGTAAACGTG CAGAGCACAT ACCCAGGTTC AACGTATGCC 960
AGCTTAAACG GTACATCGAT GGCTACTCCT CATGTTGCAG GTGCAGCAGC CCTTGTTAAA 1020
CAAAAGAACC CATCTTGGTC CAATGTACAA ATCCGCAATC ATCTAAAGAA TACGGCAACG 1080
AGCTTAGGAA GCACGAACTT GTATGGAAGC GGACTTGTCA ATGCAGAAGC GGCAACACGC 1140
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1140 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
ATGAAGAAAC CGTTGGGGAA AATTGTCGCA AGCACCGCAC TACTCATTTC TGTTGCTTTT 60
AGTTCATCGA TCGCATCGGC TGCTGAAGAA GCAAAAGAAA AATATTTAAT TGGCTTTAAT 120
GAGCAGGAAG CTGTCAGTGA GTTTGTAGAA CAAGTAGAGG CAAATGACGA GGTCGCCATT 180
CTCTCTGAGG AAGAGGAAGT CGAAATTGAA TTGCTTCATG AATTTGAAAC GATTCCTGTT 240
TTATCCGTTG AGTTAAGCCC AGAAGATGTG GACGCGCTTG AACTCGATCC AGCGATTTCT 300
TATATTGAAG AGGATGCAGA AGTAACGACA ATGGCGCAAT CAGTGCCATG GGGAATTAGC 360
CGTGTGCAAG CCCCAGCTGC CCATAACCGT GGATTGACAG GTTCTGGTGT AAAAGTTGCT 420
GTCCTCGATA CAGGTATTTC CACTCATCCA GACTTAAATA TTCGTGGTGG CGCTAGCTTT 480
GTACCAGGGG AACCATCCAC TCAAGATGGG AATGGGCATG GCACGCATGT GGCCGGGACG 540
ATTGCTGCTT TAGACAACTC GATTGGCGTT CTTGGCGTAG CGCCGAGCGC GGAACTATAC 600
GCTGTTAAAG TATTAGGGGC GAGCGGTTCA GGCGCCATCA GCTCGATTGC CCAAGGATTG 660
GAATGGGCAG GGAACAATGG CATGCACGTT GCTAATTTGA GTTTAGGAAG CCCTTCGCCA 720
AGTGCCACAC TTGAGCAAGC TGTTAATAGC GCGACTTCTA GAGGCGTTCT TGTTGTAGCG 780
GCATCTGGGA ATTCAGGTGC AGGCTCAATC AGCTATCCGG CCCGTTATGC GAACGCAATG 840
GCAGTCGGAG CTACTGACCA AAACAACAAC CGCGCCAGCT TTTCACAGTA TGGCGCAGGG 900
CTTGACATTG TCGCACCAGG TGTAAACGTG CAGAGCACAT ACCCAGGTTC AACGTATGCC 960
AGCTTAAACG GTACATCGAT GGCTACTCCT CATGTTGCAG GTGCAGCAGC CCTTGTTAAA 1020
CAAAAGAACC CATCTTGGTC CAATGTACAA ATCCGCAATC ATCTAAAGAA TACGGCAACG 1080
AGCTTAGGAA GCACGAACTT GTATGGAAGC GGACTTGTCA ATGCAGAAGC GGCAACACGC 1140
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
TATGCCAGCC ACAACGGTAC TTCGATGGCT 30
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
CACAGTTGCG GCTCTAGATA ACTCAATCGG T 31 (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
GCTGACGGTT CCGGCGCTAT TAGTTGGATC ATT 33

Claims

WHAT IS CLAIMED IS:
1. A carbonyl hydrolase variant having an amino acid sequence not found in nature derived from a precursor carbonyl hydrolase comprising a substitution of a different amino acid for a plurality of amino acid residues at a position in said precursor carbonyl hydrolase equivalent to +76 in Bacillus amyloliquefaciens subtilisin, in combination with one or more amino acid residue positions equivalent to those selected from the group consisting of +99, +101, +103, +104, +107, +123, +27, +105, +109, +126, +128, +135, +156, +166, +195, +197, +204, +206, +210, +216, +217, +218, +222, +260, +265 and/or +274 in Bacillus amyloliquefaciens subtilisin.
2. A variant according to Claim 1 wherein the precursor carbonyl hydrolase is a subtilisin.
3. A subtilisin variant according to Claim 2 wherein a
combination of substitutions is made at the positions
equivalent to 76/99, 76/101, 76/103, 76/104, 76/107, 76/123, 76/99/101, 76/99/103, 76/99/104, 76/101/103, 76/101/104, 76/103/104, 76/104/107, 76/104/123, 76/107/123, 76/99/101/103, 76/99/101/104, 76/99/103/104, 76/101/103/104, 76/103/104/123, 76/104/107/123, 76/99/101/103/104, 76/99/103/104/123,
76/99/101/103/104/123, 76/103/104/126, 76/103/104/135,
76/103/104/197, 76/103/104/222, 76/103/104/260,
76/103/104/265, 76/103/104/126/265, 27/76/104/123/274,
27/76/104/109/123/274, 27/76/104/123/218/274, 27/76/104/123, 27/76/104/107/123, 27/76/104/109/123,
27/76/104/109/123/218/274, 27/76/104/123/197,
27/76/104/123/204, 27/76/104/123/206, 27/76/104/123/216, 27/76/104/123/218, 27/76/104/123/260, 27/76/104/123/195/197, 27/76/104/123/195/218, 27/76/104/123/197/218,
27/76/104/123/204/218, 27/76/104/123/206/218,
27/76/104/123/218/260, 27/76/104/123/195/197/218,
76/103/104/217, 76/103/104/156, 76/103/104/166,
76/103/104/105, 76/101/103/104, 76/103/104/128,
76/103/104/210, 76/103/104/107, 76/103/104/204, 76/217,
76/103/104/156/166 and 76/103/104/128.
4. A subtilisin variant according to Claim 3 wherein a
combination of substitutions is made at the positions equivalent to 76/99, 76/101, 76/103, 76/104, 76/107, 76/123, 76/99/101, 76/99/103, 76/99/104, 76/101/103, 76/101/104, 76/103/104, 76/104/107, 76/104/123, 76/107/123, 76/99/101/103, 76/99/101/104, 76/99/103/104, 76/101/103/104, 76/103/104/123, 76/104/107/123, 76/99/101/103/104, 76/99/103/104/123;
76/99/101/103/104/123; 76/103/104/128; 76/103/104/260;
76/103/104/265; 76/103/104/197; 76/103/104/105;
76/103/104/135; 76/103/104/126; 76/103/104/107;
76/103/104/210; 76/103/104/126/265 and/or 76/103/104/222.
5. A subtilisin variant according to Claim 4 selected from the group consisting of 76/99, 76/104, 76/99/104, 76/103/104, 76/104/107, 76/101/103/104, 76/99/101/103/104 and 76/101/104.
6. A subtilisin variant according to Claim 4 wherein the
subtilisin variants comprise: N76D/S99D; N76D/S101R;
N76D/Ξ103A; N76D/V104I; N76D/I107V; N76D/N123S;
N76D/S99D/S101R; N76D/S99D/S103A; N76D/S99D/V104I;
N76D/S101R/S103A; N76D/S101R/V104I; N76D/S103A/V104I;
N76D/V104I/I107V; N76D/V104Y/I107V; N76D/V104I/N123S;
N76D/I107V/N123S; N76D/S99D/S101R/S103A;
N76D/S99D/S101R/V104I; N76D/S99D/S103A/V104I;
N76D/S101R/S103A/V104I; N76D/S103A/V104I/N123S;
N76D/V104I/I107V/N123S; N76D/S99D/S101R/S103A/V104I;
N76D/S99D/S103A/V104I/N123S;
N76D/S99D/S101R/S103A/V104I/N123S; N76D/S103A/V104I/S128G; N76D/S103A/V104I/T260P; N76D/S103A/V104I/S265N;
N76D/S103A/V104I/D197E; N76D/S103A/V104I/S105A;
N76D/S103A/V104I/L135I; N76D/S103A/V104I/L126F;
N76D/S103A/V104T/L107T; N76D/S103A/V104I/P210I;
N76D/S103A/V104I/L126F/S265N and N76D/S103A/V104I/M222A.
7. A subtilisin variant of Claim 5 wherein the subtilisin
variants comprise N76D/S99D, N76D/V104I, N76D/S99D/V104I, N76D/S103A/V104I, N76D/V104I/I107V, N76D/V104Y/I107V,
N76D/S101R/S103A/V104I, N76D/S99D/S101R/S103A/V104I and
N76D/S101R/V104I.
8. A subtilisin variant according to Claim 2 which is derived from a Bacillus subtilisin.
9. A subtilisin variant according to Claim 8 which is derived from Bacillus lentus subtilisin.
10. DNA encoding a carbonyl hydrolase variant of Claim 1.
11. Expression vector encoding the DNA of Claim 10.
12. Host cell transformed with the expression vector of Claim 11,
PCT/US1994/011562 1993-10-14 1994-10-13 Subtilisin variants WO1995010615A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP51201395A JP4086207B2 (en) 1993-10-14 1994-10-13 Subtilisin mutant
KR1019960701923A KR100344976B1 (en) 1993-10-14 1994-10-13 Subtilisin variants
DK94931345T DK0723590T3 (en) 1993-10-14 1994-10-13 subtilisin
BR9407825A BR9407825A (en) 1993-10-14 1994-10-13 Carbonyl hydrolase variant having an amino acid sequence not found in nature derived from a precursor carbonyl hydrolase subtilisin variant DNA expression vector and host cell
AU80157/94A AU700373B2 (en) 1993-10-14 1994-10-13 Subtilisin variants
PL94313942A PL178478B1 (en) 1993-10-14 1994-10-13 Subtilisin varieties
AT94931345T ATE284962T1 (en) 1993-10-14 1994-10-13 SUBTILISIN VARIANTS
DE69434187T DE69434187T2 (en) 1993-10-14 1994-10-13 SUBTILISIN VARIANTS
EP94931345A EP0723590B1 (en) 1993-10-14 1994-10-13 Subtilisin variants
CA002173973A CA2173973C (en) 1993-10-14 1994-10-13 Subtilisin variants
RU96109372A RU2136756C1 (en) 1993-10-14 1994-10-13 Modified subtilysine, dna encoding modified subtilysine, expression vector encoding dna and strain of host cell culture
FI961631A FI119697B (en) 1993-10-14 1996-04-12 Subtilis variants
NO19961468A NO325568B1 (en) 1993-10-14 1996-04-12 Subtilis variants, DNA, expression vector and host cell.
HK97102150A HK1000649A1 (en) 1993-10-14 1997-11-11 Subtilisin variants.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13724093A 1993-10-14 1993-10-14
US08/137,240 1993-10-14

Publications (1)

Publication Number Publication Date
WO1995010615A1 true WO1995010615A1 (en) 1995-04-20

Family

ID=22476438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/011562 WO1995010615A1 (en) 1993-10-14 1994-10-13 Subtilisin variants

Country Status (24)

Country Link
US (2) US6586221B2 (en)
EP (2) EP1526182A3 (en)
JP (1) JP4086207B2 (en)
KR (1) KR100344976B1 (en)
CN (1) CN1056649C (en)
AT (1) ATE284962T1 (en)
AU (1) AU700373B2 (en)
BR (1) BR9407825A (en)
CA (1) CA2173973C (en)
CZ (1) CZ289323B6 (en)
DE (1) DE69434187T2 (en)
DK (1) DK0723590T3 (en)
ES (1) ES2235164T3 (en)
FI (1) FI119697B (en)
HK (1) HK1000649A1 (en)
MA (1) MA23346A1 (en)
NO (1) NO325568B1 (en)
NZ (1) NZ274998A (en)
PL (1) PL178478B1 (en)
PT (1) PT723590E (en)
RU (1) RU2136756C1 (en)
TW (1) TW448230B (en)
WO (1) WO1995010615A1 (en)
ZA (1) ZA948086B (en)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687733A1 (en) * 1994-06-16 1995-12-20 The Procter & Gamble Company Detergent composition containing wool compatible high alkaline proteases
WO1996034935A2 (en) * 1995-05-05 1996-11-07 Unilever N.V. Subtilisin variants
US5677272A (en) * 1993-10-14 1997-10-14 The Procter & Gamble Company Bleaching compositions comprising protease enzymes
US5679630A (en) * 1993-10-14 1997-10-21 The Procter & Gamble Company Protease-containing cleaning compositions
WO1997042293A1 (en) * 1996-05-03 1997-11-13 The Procter & Gamble Company Liquid laundry detergent compositions comprising cotton soil release polymers and protease enzymes
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
WO1998055634A1 (en) * 1997-06-04 1998-12-10 The Procter & Gamble Company Protease enzymes for tough cleaning and/or spot and film reduction and compositions incorporating same
WO1998055579A1 (en) * 1997-06-04 1998-12-10 The Procter & Gamble Company Mixed protease enzyme systems for cleaning protein based soils and compositions incorporating same
WO1998055577A1 (en) * 1997-06-04 1998-12-10 The Procter & Gamble Company Detersive enzyme particles having water-soluble carboxylate barrier layer and compositions including same
WO1999020770A3 (en) * 1997-10-23 1999-09-02 Genencor Int Multiply-substituted protease variants
WO1999034011A3 (en) * 1997-12-24 2000-02-10 Genencor Int Method of assaying for a preferred enzyme and/or detergent
US6066611A (en) * 1994-10-13 2000-05-23 The Procter & Gamble Company Bleaching compositions comprising protease enzymes
US6187739B1 (en) 1995-09-21 2001-02-13 Henkel Kommanditgesellschaft Auf Aktien Paste-form washing and cleaning agents
WO2001018165A1 (en) * 1999-09-09 2001-03-15 The Procter & Gamble Company A detergent composition containing a protease
US6248708B1 (en) 1996-09-05 2001-06-19 Henkel-Ecolab Gmbh & Co. Ohg Paste-form detergent containing a mixture of ethoxylated alcohols
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6300116B1 (en) * 1996-11-04 2001-10-09 Novozymes A/S Modified protease having improved autoproteolytic stability
US6329333B1 (en) 1997-01-30 2001-12-11 Henkel-Ecolab Gmbh & Co. Ohg Pastelike detergent and cleaning agent
WO2001068821A3 (en) * 2000-03-14 2002-04-04 Novozymes As Novel subtilase enzymes having an improved wash performance on egg stains
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6509021B1 (en) * 1995-08-23 2003-01-21 Henkel Kommanditgesellschaft Auf Aktien Use of mutated subtilisin protease in cosmetic products
US6566115B1 (en) 1999-07-22 2003-05-20 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
US6569663B1 (en) 1998-03-26 2003-05-27 The Procter & Gamble Company Serine protease variants having amino acid substitutions
US6586223B1 (en) 1999-07-22 2003-07-01 The Procter & Gamble Company Subtilisin protease variants having amino acid substitutions in defined epitope regions
US6586224B1 (en) 1999-07-22 2003-07-01 The Procter & Gamble Company Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
US6599731B1 (en) 1997-12-30 2003-07-29 Genencor International, Inc. Proteases from gram positive organisms
US6627592B1 (en) 1998-12-15 2003-09-30 Ecolab Gmbh & Co. Ohg Pasty washing agent
US6794179B2 (en) 1997-12-30 2004-09-21 Genencor International, Inc. Proteases from gram positive organisms
EP1523553A2 (en) * 2002-01-16 2005-04-20 Genencor International, Inc. Multiply-substituted protease variants
EP1530631A2 (en) * 2002-01-16 2005-05-18 Genencor International, Inc. Multiply-substituted protease variants
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
US7033817B2 (en) 1997-12-30 2006-04-25 Genencor International, Inc. Proteases from gram positive organisms
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
AU2002325461B2 (en) * 1997-10-23 2006-05-11 Genencor International, Inc. Multiply-substituted protease variants with altered net charge for use in detergents
US7078216B2 (en) 1997-12-30 2006-07-18 Genencor International, Inc. Proteases from gram positive organisms
US7153820B2 (en) 2001-08-13 2006-12-26 Ecolab Inc. Solid detergent composition and method for solidifying a detergent composition
US7303907B2 (en) 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
WO2012160498A2 (en) 2011-05-20 2012-11-29 Ecolab Usa Inc. Acid formulations for use in a system for warewashing
EP2617804A1 (en) 2007-02-15 2013-07-24 Ecolab Inc. Fast dissolving solid detergent
US8569035B2 (en) 2001-07-12 2013-10-29 Novozymes A/S Subtilase variants
EP2677023A2 (en) 2007-10-18 2013-12-25 Ecolab Inc. Pressed, waxy, solid cleaning compositions and methods of making them
EP2792737A1 (en) 2011-05-20 2014-10-22 Ecolab USA Inc. Non-phosphate detergents and non-phosphoric acids in an alternating alkali/acid system for warewashing
US20150031114A1 (en) * 2012-02-17 2015-01-29 Henkel Ag & Co. Kgaa Detergent compositions comprising subtilase variants
WO2015032447A1 (en) 2013-09-09 2015-03-12 Ecolab Usa Inc. Synergistic stain removal through novel chelator combination
WO2015032451A1 (en) 2013-09-09 2015-03-12 Ecolab Usa Inc. Synergistic stain removal through novel chelator combination
EP2569409B1 (en) 2010-05-12 2015-11-25 Basf Se Storage-stable liquid detergent or cleaning agent containing protease and lipase
WO2016087617A1 (en) * 2014-12-04 2016-06-09 Novozymes A/S Subtilase variants and polynucleotides encoding same
EP3061817A1 (en) * 2009-04-30 2016-08-31 Kao Corporation Alkaline protease variants
EP3260537A1 (en) * 2010-12-17 2017-12-27 Basf Se Storage-stable liquid washing or cleaning agent containing protease and cellulase
EP3282004A1 (en) 2011-12-13 2018-02-14 Ecolab USA Inc. Warewashing method
EP3470516A1 (en) 2012-09-10 2019-04-17 Ecolab USA Inc. Stable liquid manual dishwashing compositions containing enzymes
US10626388B2 (en) 2014-07-04 2020-04-21 Novozymes A/S Subtilase variants and polynucleotides encoding same
EP3666870A1 (en) 2013-10-24 2020-06-17 Ecolab USA Inc. Compositions and methods for removing soils from surfaces
WO2021022045A1 (en) 2019-07-31 2021-02-04 Ecolab Usa Inc. Personal protective equipment free delimer compositions
WO2021081547A3 (en) * 2019-10-24 2021-06-03 The Procter & Gamble Company Automatic dishwashing detergent composition comprising a protease
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4446411A1 (en) * 2023-04-14 2024-10-16 Peaccel Variant subtilisin proteases

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA23346A1 (en) * 1993-10-14 1995-04-01 Genencor Int VARIANTS OF THE SUB-USE
ES2367505T3 (en) * 1997-10-23 2011-11-04 Danisco Us Inc. PROTEASE VARIANTS WITH MULTIPLE SUBSTITUTIONS WITH ALTERED NET LOAD FOR USE IN DETERGENTS.
EP1141205B1 (en) * 1998-12-18 2007-02-28 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having an additional amino acid residue in the active site loop region
DK1141335T3 (en) 1998-12-21 2009-11-09 Genencor Int Chemically modified enzymes with multiple charged variants
JP2003516751A (en) * 1999-12-15 2003-05-20 ノボザイムス アクティーゼルスカブ Subtilase variants exhibiting improved cleaning performance on egg stains
CA2394971C (en) * 1999-12-15 2016-01-19 Novozymes A/S Subtilase variants having an improved wash performance on egg stains
RU2311458C2 (en) * 2001-03-23 2007-11-27 Джененкор Интернэшнл, Инк. Proteins causing alternated immunogenic response and methods for their preparing and using
US20030157645A1 (en) * 2001-12-21 2003-08-21 Direvo Bio Tech Ag. Subtilisin variants with improved characteristics
WO2003057713A2 (en) * 2001-12-31 2003-07-17 Genencor International, Inc. Proteases producing an altered immunogenic response and methods of making and using the same
US7507569B2 (en) * 2003-05-07 2009-03-24 Novozymes A/S Variant subtilisin enzymes (subtilases)
US20090060933A1 (en) * 2004-06-14 2009-03-05 Estell David A Proteases producing an altered immunogenic response and methods of making and using the same
EP2059591B1 (en) * 2006-07-18 2012-09-05 Danisco US Inc. Dishwashing composition that contains a protease variant
US20100105598A1 (en) * 2006-10-16 2010-04-29 Pieter Augustinus Non-Phosphate Dish Detergents
EP2578680B1 (en) * 2008-06-06 2016-04-27 Danisco US Inc. Compositions and methods comprising variant microbial proteases
EP2362902B1 (en) * 2008-11-11 2012-10-24 Danisco US, Inc., Genencor Division Compositions and methods comprising a subtilisin variant
WO2010056653A2 (en) * 2008-11-11 2010-05-20 Danisco Us Inc. Proteases comprising one or more combinable mutations
DE102009029513A1 (en) * 2009-09-16 2011-03-24 Henkel Ag & Co. Kgaa Storage-stable liquid washing or cleaning agent containing proteases
US20130260438A1 (en) * 2010-05-06 2013-10-03 Danisco Us Inc. Compositions and methods comprising serine protease variants (as amended)
DE102010063458A1 (en) * 2010-12-17 2012-06-21 Henkel Ag & Co. Kgaa Storage stable liquid washing or cleaning agent containing protease and amylase
BR112013027963A2 (en) * 2011-05-05 2016-11-29 Danisco Us Inc "Subtilisin variant with proteolytic activity, nucleic acid, expression vector, host cell, composition and cleaning method".
DE102012201522A1 (en) * 2012-02-02 2013-08-08 Basf Se Storage stable liquid dishwashing detergent containing protease and amylase
DE102012215107A1 (en) * 2012-08-24 2014-02-27 Basf Se Solid dishwashing detergent with improved protease performance
CN103013960A (en) * 2012-12-21 2013-04-03 青岛蔚蓝生物集团有限公司 Alkaline protease and recombinant expression engineering bacterium thereof
WO2016183509A1 (en) * 2015-05-13 2016-11-17 Danisco Us Inc. AprL-CLADE PROTEASE VARIANTS AND USES THEREOF
BR112018010475B1 (en) 2015-11-25 2023-02-14 Unilever Ip Holdings B.V. LIQUID DETERGENT COMPOSITION AND LAUNDRY WASHING METHOD USING A LIQUID WASHING DETERGENT COMPOSITION
US11661567B2 (en) * 2016-05-31 2023-05-30 Danisco Us Inc. Protease variants and uses thereof
US20190185836A1 (en) * 2016-09-02 2019-06-20 The Regents Of The University Of California Engineered subtiligase variants for versatile, site-specific labeling of proteins
CN111373039A (en) * 2017-11-29 2020-07-03 丹尼斯科美国公司 Subtilisin variants having improved stability
CN114836408B (en) * 2022-05-28 2023-09-19 湖北大学 Alkaline protease containing propeptide mutant and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251446A2 (en) * 1986-04-30 1988-01-07 Genencor International, Inc. Non-human Carbonyl hydrolase mutants, DNA sequences and vectors encoding same and hosts transformed with said vectors
WO1988008028A1 (en) * 1987-04-06 1988-10-20 Genex Corporation The engineering of electrostatic interactions at metal ion binding sites for the stabilization of proteins
WO1989009819A1 (en) * 1988-04-12 1989-10-19 Genex Corporation Combining mutations for stabilization of subtilisin
EP0398539A1 (en) * 1989-05-17 1990-11-22 Amgen Inc. Multiply mutated subtilisins
EP0405901A1 (en) * 1989-06-26 1991-01-02 Unilever Plc Enzymatic detergent compositions
EP0405902A1 (en) * 1989-06-26 1991-01-02 Unilever Plc Enymatic detergent compositions
WO1991006637A1 (en) * 1989-10-31 1991-05-16 Genencor International, Inc. Subtilisin mutants
WO1992008778A1 (en) * 1990-11-14 1992-05-29 Novo Nordisk A/S Detergent compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
US5155033A (en) 1989-01-06 1992-10-13 Genencor, Inc. Subtilisins modified at position 225 resulting in a shift in catalytic activity
US5182204A (en) 1984-05-29 1993-01-26 Genencor International, Inc. Non-human carbonyl hydrolase mutants, vectors encoding same and hosts transformed with said vectors
US5204015A (en) 1984-05-29 1993-04-20 Genencor International, Inc. Subtilisin mutants
US5700676A (en) * 1984-05-29 1997-12-23 Genencor International Inc. Modified subtilisins having amino acid alterations
US5972682A (en) * 1984-05-29 1999-10-26 Genencor International, Inc. Enzymatically active modified subtilisins
US5013657A (en) 1988-04-12 1991-05-07 Bryan Philip N Subtilisin mutations
US4914031A (en) 1987-04-10 1990-04-03 Amgen, Inc. Subtilisin analogs
DK6488D0 (en) 1988-01-07 1988-01-07 Novo Industri As ENZYMES
AU3063389A (en) 1988-01-08 1989-08-01 Dpz Deutsches Primatenzentrum Gesellschaft M.B.H. Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
PT89702B (en) 1988-02-11 1994-04-29 Gist Brocades Nv PROCESS FOR PREPARING NEW PROTEOLITIC ENZYMES AND DETERGENTS THAT CONTAINS THEM
US5324653A (en) 1988-02-11 1994-06-28 Gist-Brocades N.V. Recombinant genetic means for the production of serine protease muteins
US5116741A (en) * 1988-04-12 1992-05-26 Genex Corporation Biosynthetic uses of thermostable proteases
US5665587A (en) * 1989-06-26 1997-09-09 Novo Nordisk A/S Modified subtilisins and detergent compositions containing same
DK316989D0 (en) 1989-06-26 1989-06-26 Novo Nordisk As ENZYMES
JP2567282B2 (en) * 1989-10-02 1996-12-25 日本ゼオン株式会社 Positive resist composition
EP0563169B2 (en) 1990-12-21 2006-04-12 Novozymes A/S ENZYME MUTANTS HAVING A LOW DEGREE OF VARIATION OF THE MOLECULAR CHARGE OVER A pH RANGE
US5340735A (en) 1991-05-29 1994-08-23 Cognis, Inc. Bacillus lentus alkaline protease variants with increased stability
US5316935A (en) * 1992-04-06 1994-05-31 California Institute Of Technology Subtilisin variants suitable for hydrolysis and synthesis in organic media
AU682314B2 (en) 1992-07-17 1997-10-02 Genencor International, Inc. High alkaline serine proteases
DK39093D0 (en) 1993-04-01 1993-04-01 Novo Nordisk As ENZYME
MA23346A1 (en) * 1993-10-14 1995-04-01 Genencor Int VARIANTS OF THE SUB-USE
US5679630A (en) * 1993-10-14 1997-10-21 The Procter & Gamble Company Protease-containing cleaning compositions
CZ105296A3 (en) * 1993-10-14 1996-09-11 Procter & Gamble Bleaching agent containing protease enzymes, cleansing agents, agent for cleaning fabrics and fabric cleaning method
MA25044A1 (en) * 1997-10-23 2000-10-01 Procter & Gamble WASHING COMPOSITIONS CONTAINING MULTISUBSTITUTED PROTEASE VARIANTS.
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
DK1141335T3 (en) * 1998-12-21 2009-11-09 Genencor Int Chemically modified enzymes with multiple charged variants
RU2311458C2 (en) * 2001-03-23 2007-11-27 Джененкор Интернэшнл, Инк. Proteins causing alternated immunogenic response and methods for their preparing and using

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251446A2 (en) * 1986-04-30 1988-01-07 Genencor International, Inc. Non-human Carbonyl hydrolase mutants, DNA sequences and vectors encoding same and hosts transformed with said vectors
WO1988008028A1 (en) * 1987-04-06 1988-10-20 Genex Corporation The engineering of electrostatic interactions at metal ion binding sites for the stabilization of proteins
WO1989009819A1 (en) * 1988-04-12 1989-10-19 Genex Corporation Combining mutations for stabilization of subtilisin
EP0398539A1 (en) * 1989-05-17 1990-11-22 Amgen Inc. Multiply mutated subtilisins
EP0405901A1 (en) * 1989-06-26 1991-01-02 Unilever Plc Enzymatic detergent compositions
EP0405902A1 (en) * 1989-06-26 1991-01-02 Unilever Plc Enymatic detergent compositions
WO1991006637A1 (en) * 1989-10-31 1991-05-16 Genencor International, Inc. Subtilisin mutants
WO1992008778A1 (en) * 1990-11-14 1992-05-29 Novo Nordisk A/S Detergent compositions

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 91, no. 9, 1991, Philadelphia, PA, US; abstract no. 95173, L. NARHI ET AL: "Enhanced stability of subtilisin by three point mutations" page 385; *
BIOTECHNOL. APPL. BIOCHEM., vol. 13, no. 1, 1991, pages 12 - 24 *
J. WELLS ET AL: "Designing substrate specificity by protein engineering of electrostatic interactions", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 84, March 1987 (1987-03-01), WASHINGTON US, pages 1219 - 1223 *
M. PANTOLIANO ET AL: "Large increases in general stability for subtilisin BPN' through incremental changes in the free energy of unfolding", BIOCHEMISTRY., vol. 28, 1989, EASTON, PA US, pages 7205 - 7213 *
R. BOTT ET AL: "Using structural comparison as a guide in protein engineering", ANNALS OF THE NEW YORK ACADAMY OF SCIENCES, vol. 672, 1992, pages 10 - 19 *
R. SIEZEN ET AL: "Homology modelling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteases", PROTEIN ENGINEERING, vol. 4, no. 7, 1991, pages 719 - 737 *
T. GRAYCAR ET AL: "Altering the proteolytic activity of subtilisin through protein engineering", ANNALS OF THE NEW YORK ACADAMY OF SCIENCES, vol. 672, 1992, pages 71 - 79 *

Cited By (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017871A (en) * 1993-10-14 2000-01-25 The Procter & Gamble Company Protease-containing cleaning compositions
US5677272A (en) * 1993-10-14 1997-10-14 The Procter & Gamble Company Bleaching compositions comprising protease enzymes
US5679630A (en) * 1993-10-14 1997-10-21 The Procter & Gamble Company Protease-containing cleaning compositions
EP0687733A1 (en) * 1994-06-16 1995-12-20 The Procter & Gamble Company Detergent composition containing wool compatible high alkaline proteases
US6066611A (en) * 1994-10-13 2000-05-23 The Procter & Gamble Company Bleaching compositions comprising protease enzymes
WO1996034935A2 (en) * 1995-05-05 1996-11-07 Unilever N.V. Subtilisin variants
WO1996034935A3 (en) * 1995-05-05 1997-01-16 Unilever Nv Subtilisin variants
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
US6509021B1 (en) * 1995-08-23 2003-01-21 Henkel Kommanditgesellschaft Auf Aktien Use of mutated subtilisin protease in cosmetic products
US6187739B1 (en) 1995-09-21 2001-02-13 Henkel Kommanditgesellschaft Auf Aktien Paste-form washing and cleaning agents
WO1997042293A1 (en) * 1996-05-03 1997-11-13 The Procter & Gamble Company Liquid laundry detergent compositions comprising cotton soil release polymers and protease enzymes
JPH11508318A (en) * 1996-05-03 1999-07-21 ザ、プロクター、エンド、ギャンブル、カンパニー Liquid laundry detergent composition containing cotton soil release polymer and protease enzyme
US6248708B1 (en) 1996-09-05 2001-06-19 Henkel-Ecolab Gmbh & Co. Ohg Paste-form detergent containing a mixture of ethoxylated alcohols
US7098017B2 (en) * 1996-11-04 2006-08-29 Novozymes A/S Protease variants and compositions
US6300116B1 (en) * 1996-11-04 2001-10-09 Novozymes A/S Modified protease having improved autoproteolytic stability
US6329333B1 (en) 1997-01-30 2001-12-11 Henkel-Ecolab Gmbh & Co. Ohg Pastelike detergent and cleaning agent
WO1998055577A1 (en) * 1997-06-04 1998-12-10 The Procter & Gamble Company Detersive enzyme particles having water-soluble carboxylate barrier layer and compositions including same
WO1998055579A1 (en) * 1997-06-04 1998-12-10 The Procter & Gamble Company Mixed protease enzyme systems for cleaning protein based soils and compositions incorporating same
WO1998055634A1 (en) * 1997-06-04 1998-12-10 The Procter & Gamble Company Protease enzymes for tough cleaning and/or spot and film reduction and compositions incorporating same
US6369011B1 (en) * 1997-06-04 2002-04-09 The Procter & Gamble Company Protease enzymes for tough cleaning and/or spot and film reduction and compositions incorporating same
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
CZ302287B6 (en) * 1997-10-23 2011-02-09 Genencor International, Inc. Subtilisin variant
EP1571199A2 (en) 1997-10-23 2005-09-07 Genencor International, Inc. Multiply-substituted protease variants
US6312936B1 (en) 1997-10-23 2001-11-06 Genencor International, Inc. Multiply-substituted protease variants
AU2002325461B2 (en) * 1997-10-23 2006-05-11 Genencor International, Inc. Multiply-substituted protease variants with altered net charge for use in detergents
EP1624050A3 (en) * 1997-10-23 2006-06-21 Genencor International, Inc. Multiply-substituted protease variants
CZ300347B6 (en) * 1997-10-23 2009-04-29 Genencor International, Inc. Method of increasing subtilisin activity and process for preparing a detergent
EP1624050A2 (en) 1997-10-23 2006-02-08 Genencor International, Inc. Multiply-substituted protease variants
US6815193B2 (en) 1997-10-23 2004-11-09 Genencor International, Inc. Multiply-substituted protease variants
US6927055B2 (en) 1997-10-23 2005-08-09 Genencor International, Inc. Multiply-substituted protease variants
EP1571199A3 (en) * 1997-10-23 2006-01-11 Genencor International, Inc. Multiply-substituted protease variants
CZ301469B6 (en) * 1997-10-23 2010-03-17 Genencor International, Inc. Subtilisin and composition containing thereof
WO1999020770A3 (en) * 1997-10-23 1999-09-02 Genencor Int Multiply-substituted protease variants
US7122334B2 (en) 1997-12-24 2006-10-17 Genencor International, Inc. Method of assaying wash performance of enzymes on a microtiter plate
WO1999034011A3 (en) * 1997-12-24 2000-02-10 Genencor Int Method of assaying for a preferred enzyme and/or detergent
US7098021B2 (en) 1997-12-30 2006-08-29 Genencor International, Inc. Proteases from gram positive organisms
US6599731B1 (en) 1997-12-30 2003-07-29 Genencor International, Inc. Proteases from gram positive organisms
US7078372B2 (en) 1997-12-30 2006-07-18 Genencor International, Inc. Proteases from gram positive organisms
US7070990B2 (en) 1997-12-30 2006-07-04 Genencor International, Inc. Proteases from GRAM positive organisms
US6794179B2 (en) 1997-12-30 2004-09-21 Genencor International, Inc. Proteases from gram positive organisms
US7070819B2 (en) 1997-12-30 2006-07-04 Genencor International, Inc. Proteases from gram positive organisms
US7078216B2 (en) 1997-12-30 2006-07-18 Genencor International, Inc. Proteases from gram positive organisms
US6872807B2 (en) 1997-12-30 2005-03-29 Genencor International, Inc. Proteases from gram positive organisms
US7033817B2 (en) 1997-12-30 2006-04-25 Genencor International, Inc. Proteases from gram positive organisms
US7070986B2 (en) 1997-12-30 2006-07-04 Genencor International, Inc. Proteases from gram positive organisms
US6569663B1 (en) 1998-03-26 2003-05-27 The Procter & Gamble Company Serine protease variants having amino acid substitutions
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6627592B1 (en) 1998-12-15 2003-09-30 Ecolab Gmbh & Co. Ohg Pasty washing agent
US6586223B1 (en) 1999-07-22 2003-07-01 The Procter & Gamble Company Subtilisin protease variants having amino acid substitutions in defined epitope regions
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
US6566115B1 (en) 1999-07-22 2003-05-20 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
US6586224B1 (en) 1999-07-22 2003-07-01 The Procter & Gamble Company Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
WO2001018165A1 (en) * 1999-09-09 2001-03-15 The Procter & Gamble Company A detergent composition containing a protease
AU2001239214B8 (en) * 2000-03-14 2006-07-20 Maxygen, Inc. Novel subtilase enzymes having an improved wash performance on egg stains
US6777218B1 (en) 2000-03-14 2004-08-17 Novozymes A/S Subtilase enzymes having an improved wash performance on egg stains
AU2001239214B2 (en) * 2000-03-14 2006-06-08 Maxygen, Inc. Novel subtilase enzymes having an improved wash performance on egg stains
WO2001068821A3 (en) * 2000-03-14 2002-04-04 Novozymes As Novel subtilase enzymes having an improved wash performance on egg stains
US8110391B2 (en) 2001-01-08 2012-02-07 Health Protection Agency Degradation and detection of TSE infectivity
US7303907B2 (en) 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
US8569035B2 (en) 2001-07-12 2013-10-29 Novozymes A/S Subtilase variants
US10351837B2 (en) 2001-07-12 2019-07-16 Novozymes A/S Subtilase variants
US9528100B2 (en) 2001-07-12 2016-12-27 Novozymes A/S Subtilase variants
US7153820B2 (en) 2001-08-13 2006-12-26 Ecolab Inc. Solid detergent composition and method for solidifying a detergent composition
EP1523553A2 (en) * 2002-01-16 2005-04-20 Genencor International, Inc. Multiply-substituted protease variants
EP1523553A4 (en) * 2002-01-16 2006-06-21 Genencor Int Multiply-substituted protease variants
EP1530631A4 (en) * 2002-01-16 2006-03-08 Genencor Int Multiply-substituted protease variants
EP1530631A2 (en) * 2002-01-16 2005-05-18 Genencor International, Inc. Multiply-substituted protease variants
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP2586456A1 (en) 2004-10-29 2013-05-01 BioGeneriX AG Remodeling and glycopegylation of fibroblast growth factor (FGF)
US10577565B2 (en) 2007-02-15 2020-03-03 Ecolab Usa Inc. Fast dissolving solid detergent
EP2617804A1 (en) 2007-02-15 2013-07-24 Ecolab Inc. Fast dissolving solid detergent
EP3339412A1 (en) 2007-02-15 2018-06-27 Ecolab Usa Inc. Fast dissolving solid detergent
US10005986B2 (en) 2007-02-15 2018-06-26 Ecolab Usa Inc. Fast dissolving solid detergent
US11261406B2 (en) 2007-02-15 2022-03-01 Ecolab Usa Inc. Fast dissolving solid detergent
US9267097B2 (en) 2007-02-15 2016-02-23 Ecolab Usa Inc. Fast dissolving solid detergent
EP2677023A2 (en) 2007-10-18 2013-12-25 Ecolab Inc. Pressed, waxy, solid cleaning compositions and methods of making them
EP3438235A1 (en) 2007-10-18 2019-02-06 Ecolab USA Inc. Pressed, waxy, solid cleaning compositions and methods of making them
EP3061817A1 (en) * 2009-04-30 2016-08-31 Kao Corporation Alkaline protease variants
EP2569409B1 (en) 2010-05-12 2015-11-25 Basf Se Storage-stable liquid detergent or cleaning agent containing protease and lipase
EP3260537A1 (en) * 2010-12-17 2017-12-27 Basf Se Storage-stable liquid washing or cleaning agent containing protease and cellulase
WO2012160498A2 (en) 2011-05-20 2012-11-29 Ecolab Usa Inc. Acid formulations for use in a system for warewashing
EP2792737A1 (en) 2011-05-20 2014-10-22 Ecolab USA Inc. Non-phosphate detergents and non-phosphoric acids in an alternating alkali/acid system for warewashing
EP2902471A1 (en) 2011-05-20 2015-08-05 Ecolab USA Inc. Non-phosphate detergents and non-phosphoric acids in an alternating alkali/acid system for warewashing
EP3282004A1 (en) 2011-12-13 2018-02-14 Ecolab USA Inc. Warewashing method
US20150031114A1 (en) * 2012-02-17 2015-01-29 Henkel Ag & Co. Kgaa Detergent compositions comprising subtilase variants
EP3470516A1 (en) 2012-09-10 2019-04-17 Ecolab USA Inc. Stable liquid manual dishwashing compositions containing enzymes
WO2015032451A1 (en) 2013-09-09 2015-03-12 Ecolab Usa Inc. Synergistic stain removal through novel chelator combination
EP3279304A1 (en) 2013-09-09 2018-02-07 Ecolab USA Inc. Synergistic stain removal through novel chelator combination
EP3561034A1 (en) 2013-09-09 2019-10-30 Ecolab USA Inc. Synergistic stain removal through novel chelator combination
EP3272847A1 (en) 2013-09-09 2018-01-24 Ecolab USA Inc. Synergistic stain removal through novel chelator combination
WO2015032447A1 (en) 2013-09-09 2015-03-12 Ecolab Usa Inc. Synergistic stain removal through novel chelator combination
EP4095222A1 (en) 2013-09-09 2022-11-30 Ecolab USA Inc. Method of warewashing based on the synergistic stain removal through novel chelator combination
EP4276163A1 (en) 2013-10-24 2023-11-15 Ecolab USA Inc. Compositions and methods for removing soils from surfaces
EP3666870A1 (en) 2013-10-24 2020-06-17 Ecolab USA Inc. Compositions and methods for removing soils from surfaces
US10920209B2 (en) 2014-07-04 2021-02-16 Novozymes A/S Subtilase variants having improved storage stability
US12065680B2 (en) 2014-07-04 2024-08-20 Novozymes A/S Subtilase variants and polynucleotides encoding same
US10626388B2 (en) 2014-07-04 2020-04-21 Novozymes A/S Subtilase variants and polynucleotides encoding same
EP3164486B1 (en) * 2014-07-04 2020-05-13 Novozymes A/S Subtilase variants and polynucleotides encoding same
US11591586B2 (en) 2014-07-04 2023-02-28 Novozymes A/S Subtilase variants and polynucleotides encoding same
US11591585B2 (en) 2014-12-04 2023-02-28 Novozymes A/S Subtilase variants and polynucleotides encoding same
CN107075493A (en) * 2014-12-04 2017-08-18 诺维信公司 Subtilase variants and the polynucleotides for encoding them
CN107075493B (en) * 2014-12-04 2020-09-01 诺维信公司 Subtilase variants and polynucleotides encoding same
EP3690037A1 (en) * 2014-12-04 2020-08-05 Novozymes A/S Subtilase variants and polynucleotides encoding same
US10683491B2 (en) 2014-12-04 2020-06-16 Novozymes A/S Subtilase variants and polynucleotides encoding same
RU2710720C2 (en) * 2014-12-04 2020-01-10 Новозимс А/С Subtilase variants and polynucleotides encoding same
WO2016087617A1 (en) * 2014-12-04 2016-06-09 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2021022045A1 (en) 2019-07-31 2021-02-04 Ecolab Usa Inc. Personal protective equipment free delimer compositions
WO2021081547A3 (en) * 2019-10-24 2021-06-03 The Procter & Gamble Company Automatic dishwashing detergent composition comprising a protease
CN114585719A (en) * 2019-10-24 2022-06-03 宝洁公司 Automatic dishwashing detergent composition comprising protease
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4446411A1 (en) * 2023-04-14 2024-10-16 Peaccel Variant subtilisin proteases

Also Published As

Publication number Publication date
NZ274998A (en) 1997-04-24
CN1133068A (en) 1996-10-09
FI961631A0 (en) 1996-04-12
CA2173973A1 (en) 1995-04-20
US6586221B2 (en) 2003-07-01
PT723590E (en) 2005-04-29
DE69434187D1 (en) 2005-01-20
US7250281B2 (en) 2007-07-31
DK0723590T3 (en) 2005-04-25
US20040023353A1 (en) 2004-02-05
AU8015794A (en) 1995-05-04
EP0723590B1 (en) 2004-12-15
ES2235164T3 (en) 2005-07-01
CN1056649C (en) 2000-09-20
BR9407825A (en) 1997-05-06
DE69434187T2 (en) 2005-12-15
EP1526182A3 (en) 2005-05-04
ATE284962T1 (en) 2005-01-15
PL313942A1 (en) 1996-08-05
RU2136756C1 (en) 1999-09-10
TW448230B (en) 2001-08-01
JPH09504170A (en) 1997-04-28
US20030077807A1 (en) 2003-04-24
EP0723590A1 (en) 1996-07-31
FI119697B (en) 2009-02-13
NO961468D0 (en) 1996-04-12
FI961631A (en) 1996-04-15
KR100344976B1 (en) 2002-11-23
NO325568B1 (en) 2008-06-23
EP1526182A2 (en) 2005-04-27
PL178478B1 (en) 2000-05-31
JP4086207B2 (en) 2008-05-14
CZ289323B6 (en) 2002-01-16
AU700373B2 (en) 1999-01-07
HK1000649A1 (en) 2005-06-03
ZA948086B (en) 1995-06-07
CA2173973C (en) 2009-10-06
MA23346A1 (en) 1995-04-01
NO961468L (en) 1996-04-12
CZ106596A3 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
US6586221B2 (en) Subtilisin variants multiply-substituted subtilising variants having a substitution at position 76
EP1624050B9 (en) Multiply-substituted protease variants
US6017871A (en) Protease-containing cleaning compositions
US5185258A (en) Subtilisin mutants
US7306937B2 (en) Multiply-substituted protease variants
US20150232829A1 (en) Multiply-Substituted Protease Variants
CA2829859A1 (en) Multiply-substituted protease variants
MXPA00003806A (en) Multiply-substituted protease variants with altered net charge for use in detergents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193785.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994931345

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 274998

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2173973

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 961631

Country of ref document: FI

Ref document number: PV1996-1065

Country of ref document: CZ

Ref document number: 96-00807

Country of ref document: RO

WWP Wipo information: published in national office

Ref document number: 1994931345

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1996-1065

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1996-1065

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1994931345

Country of ref document: EP